CN1946690A

CN1946690A - Cyclobutenedione groups-containing compounds as inhibitors of hepatitis C virus NS3 serine protease

Info

Publication number: CN1946690A
Application number: CNA2005800126511A
Authority: CN
Inventors: S·L·博根; W·潘; S·阮; F·G·恩裘洛吉
Original assignee: Schering Corp
Current assignee: Merck Sharp and Dohme Corp
Priority date: 2004-02-27
Filing date: 2005-02-24
Publication date: 2007-04-11
Also published as: CA2557301A1; EP1742914A1; JP2007525521A; WO2005085197A1

Abstract

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Description

Contain the cyclobutenedione group compound as inhibitors of NS 3 serine protease of hepatitis C virus

Invention field

The present invention relates to new hepatitis C virus (" HCV ") proteinase inhibitor; The medicinal compositions that contains one or more these type of inhibitor; Prepare the method for this type of inhibitor and with the method for this type of inhibitor for treating hepatitis C and relative disease.The present invention also openly is used as the new compound of HCVNS3/NS4a serpin.The application requires the right of priority of the U.S. Provisional Patent Application sequence number (SN) 60/548,823 of submission on February 27th, 2004.

Background of invention

Hepatitis C virus (HCV) relates to non-first type, non-hepatitis B (NANBH), (+)-Yi single strand RNA virus of main pathogens among especially relevant with the blood NANBH (BB-NANBH) (referring to, international application published WO 89/04669 and European patent application published EP 381216).NANBH is different with the hepatopathy that other class C-type virus C causes, for example hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis D virus (HDV), cytomegalovirus (CMV) and Epstein-Barr virus (EBV) also are different from for example other form hepatopathy of alcoholism and primary biliary cirrhosis.

Recently, identify, clone and give expression to polypeptide processing and the essential HCV proteolytic enzyme of virus replication.(referring to for example U.S. Patent number 5,712,145).From the N-terminal to the C-terminal, these about 3000 amino acid polyproteins contain nucleocapsid protein (C), envelope protein (E1 and E2) and some unstructuredness albumen (NS1,2,3,4a, 5a and 5b).NS3 is by about 68kda albumen of genomic about 1893 nucleotide codings of HCV, has two special territories: (a) by about 200 serine protease domains that-terminal amino acid is formed; (b) in the RNA of PROTEIN C-end dependency ATP enzyme territory.Because the similarity in protein sequence, whole three-dimensional structure and catalytic mechanism, NS3 proteolytic enzyme is considered to the member of Chymotrypsin family.Other Chymotrypsin sample enzyme is elastoser, Xa factor, zymoplasm, trypsinase, plasmin, urokinase, tPA and PSA.HCV NS3 serine protease is responsible for the proteolysis at NS3/NS4a, NS4a/NS4b, NS4b/NS5a and NS5a/NS5b joint polypeptide (polyprotein), therefore is responsible for producing 4 kinds of viral proteins during virus replication.This makes HCV NS3 serine protease become the attractive target of antiviral chemotherapy.The compounds of this invention can suppress this proteolytic enzyme.They can also regulate the processing of hepatitis C virus (HCV) polypeptide.

The NS4a albumen that has recorded about 6kda polypeptide is the cofactor of NS3 serine protease.Occur in intramolecularly (being cis) by the NS3/NS4a serine protease NS3/NS4a joint that dissociates automatically, and be intermolecular carrying out (promptly trans) at other position of dissociating.

Naturally there is halfcystine in the position analysis revealed that dissociates of HCV proteolytic enzyme and has Serine at P1 ' at P1; These residue strictnesses are retained in NS4a/NS4b, NS4b/NS5a and NS5a/NS5b joint.The NS3/NS4a joint contains Threonine at P1, contains Serine at P1 '.Suppose that Cys among the NS3/NS4a → Thr replaces and explain in this joint processing and need cis but not trans.Referring to, (1994) Proc.Natl.Acad.Sci (USA) 91:888-892 such as Pizzi for example, Failla etc. (1996) Folding ﹠amp; Design 1:35-42.The NS3/NS4a position of dissociating also more tolerates mutagenesis than other position.Referring to, (1994) J.Virol.68:7525-7533 such as Kollykhalov for example.Find that also the acidic residues in the regional upstream at the position of dissociating need effectively dissociate.Referring to, (1994) J.Virol.68:7351-7357 such as Komoda for example.

The HCV proteinase inhibitor of having reported comprises antioxidant (referring to international application published WO 98/14181), some peptide and peptide analogs are (referring to international application published WO 98/17679, Landro etc. (1997) Biochem.36:9340-9348, Ingallinella etc. (1998) Biochem.37:8906-8914, (1998) Bioorg.Med.Chem.Lett.8:1713-1718 such as Llin à s-Brunet), inhibitor (Martin etc. (1998) Biochem.37:11459-11468 based on 70-amino acid polypeptide eglin c, be selected from the inhibitor avidity (Dimasi etc. (1997) J.Virol.71:7461-7469) of people's pancreas secretion trypsin inhibitor (hPSTI-C3) and corpusculum repertoire (MBip), cV _HE2 (" camelized " variable domain antibody fragment) (Martin etc. (1997) Protein Eng.10:607-614) and α 1-chymotrypsin inhibitor (ACT) (Elzouki etc.) (1997) J.Hepat.27:42-28).The ribozyme that is designed to the selective destruction HCV RNA is disclosed recently (referring to BioWorld Today 9 (217): 4 (on November 10th, 1998)).

Also with reference to the PCT publication No. WO 98/17679 (Vertex Pharmaceuticals Incorporated) that announced on April 30th, 1998; The WO98/22496 (F.Hoffmann-La Roche AG) that on May 28th, 1998 announced; With the WO99/07734 (Boehringer Ingelheim Canada Ltd.) that announced on February 18th, 1999.

HCV relates to liver cirrhosis and brings out hepatocellular carcinoma.At present, the subject suffering from HCV infection prognosis is very poor.Because shortage infects relevant immunity with HCV or alleviates, HCV infects the more refractory treatment of hepatitis than other form.Present data show behind the liver cirrhosis diagnosis that the survival rate in 4 years is less than 50%.It is 10-30% that diagnosis has local resectable hepatocellular carcinoma patient 5 annual survival rates, and has local unresectable hepatocellular carcinoma patient 5 annual survival rates less than 1%.

(US 6,608,027, the transferee: Boehringer Ingelheim (Canada) Ltd. with reference to WO 00/59929; Announced on October 12nd, 2000), this patent disclosure following formula peptide derivant:

With reference to A.Marchetti etc., Synlett, S1, the dicyclo analogue of the described synthetic HCVNS3 proteinase inhibitor of 1000-1002 (1999).Wherein disclosed compound has following formula:

Also with reference to W.Han etc., Bioorganic ﹠amp; Medicinal Chem.Lett, (2000) 10,711-713 wherein describe the preparation of some alpha-keto amide that contains allyl group and ethyl functional group, alpha-ketoacid ester and α-diketone.

Also with reference to WO 00/09558 (transferee: Boehringer Ingelheim Limited; Announced on February 24th, 2000), the following formula peptide derivant is wherein disclosed:

Various key elements have been defined in its Chinese.The exemplary compounds of this series compound is:

Also with reference to WO 00/09543 (transferee: Boehringer Ingelheim Limited; Announced on February 24th, 2000), the following formula peptide derivant is wherein disclosed:

Also with reference to US 6,608,027 (Boehringer Ingelheim Canada), wherein discloses following type NS3 proteinase inhibitor:

Defined various piece in its Chinese.

At present, the therapy of treatment hepatitis C comprises alpha-interferon (INF _α) and the conjoint therapy of ribavirin and Interferon, rabbit.Referring to, (1998) Proc.Assoc.Am.Physicians 110 (2): 98-112 such as Beremguer for example.These therapies have lasting responsiveness to hang down and take place often the shortcoming of side effect.Referring to, (1997) N.Engl.J.Med.336:347 such as Hoofnagle for example.At present, there is not operational HCV to infect vaccine.

Further with reference to the WO 01/74768 that announces October 11 calendar year 2001 (transferee: Vertex Pharmaceuticals Inc), wherein openly as some following general formula compound (R defines and sees in the literary composition) of NS 3-serine protease inhibitors of hepatitis C virus:

Disclosed particular compound has following formula in aforementioned WO 01/74768:

PCT publication No. WO 01/77113; WO 01/081325; WO 02/08198; WO02/08256; WO 02/08187; WO 02/08244; WO 02/48172; WO 02/08251; With the various types of peptides and/or other compound that disclose in the pending trial U.S. Patent application sequence number (SN) of submitting on January 18th, 2,002 10/052,386 as hepatitis C virus NS-3 serpin.The disclosure of these applications is attached to herein by reference.

HCV infects needs new treatment and therapy.Need can be used for treating or preventing or alleviate the compound of one or more hepatitis C symptoms.

Need to treat or prevent or alleviate the method for one or more hepatitis C symptoms.

Need regulate serine protease, the especially method of HCVNS3/NS4a serine protease with the compound that provides herein.

Need regulate HCV polypeptide method for processing with the compound that provides herein.

Summary of the invention

In its many embodiments, the invention provides the new HCV proteinase inhibitor of a class; The medicinal compositions that contains one or more these compounds; Preparation contains the method for the pharmaceutical preparation of one or more these compounds; With with one or more these compounds or one or more this type of preparations, treatment or prevention HCV or alleviate the method for one or more hepatitis C symptoms.HCV polypeptide and the interactional method of HCV proteolytic enzyme of regulating also is provided.In compound provided herein, preferably suppress the compound of HCV NS3/NS4a serine protease.The present invention come into the open enantiomorph, steric isomer, rotational isomer, tautomer, diastereomer or the racemic modification of compound or described compound, or described compound pharmacy acceptable salt, solvate or ester, described compound has universal architecture shown in the structural formula I:

Formula I

Wherein:

R ¹Be H, OR ⁸, NR ⁹R ¹⁰Or CHR ⁹R ¹⁰, R wherein ⁸, R ⁹And R ¹⁰Can be identical or different, independently be selected from separately H, alkyl-, thiazolinyl-, alkynyl-, aryl-, assorted alkyl-, heteroaryl-, cycloalkyl-, heterocyclic radical-, aralkyl-and heteroaralkyl;

A and M can be identical or different, independently are selected from R, OR, NHR, NRR ', SR, SO separately ₂R and halogen; Or A and M be connected to each other, so that with part shown in the following formula I:

Form 3 yuan, 4 yuan, 6 yuan, 7 yuan or 8 yuan of cycloalkyl, 4 yuan of-8 yuan of heterocyclic radicals, 6 yuan of-10 yuan of aryl or 5 yuan of-10 yuan of heteroaryls;

E is C (H) or C (R);

L is C (H), C (R), CH ₂C (R) or C (R) CH ₂

R, R ', R ²And R ³Can be identical or different, independently be selected from separately H, alkyl-, thiazolinyl-, alkynyl-, cycloalkyl-, assorted alkyl-, heterocyclic radical-, aryl-, heteroaryl-, (cycloalkyl) alkyl-, (heterocyclic radical) alkyl-, aryl-alkyl-and heteroaryl-alkyl-; Perhaps, R and R ' among the NRR ' are connected to each other, so that 4 yuan of-8 yuan of heterocyclic radicals of NRR ' formation;

Be selected from the lower section with Y:

Y wherein ³⁰Be selected from:

Wherein u is numerical value 0-1;

X is selected from O, NR ¹⁵, NC (O) R ¹⁶, S, S (O) and S (O ₂);

G is NH or O; With

R ¹⁵, R ¹⁶, R ¹⁷, R ¹⁸, R ¹⁹, T ₁, T ₂And T ₃Can be identical or different, independently be selected from H, alkyl, assorted alkyl, thiazolinyl, assorted thiazolinyl, alkynyl, assorted alkynyl, cycloalkyl, heterocyclic radical, aryl, aralkyl, heteroaryl and heteroaralkyl separately, perhaps, R ¹⁷And R ¹⁸Be connected to each other and form 3 yuan of-8 yuan of cycloalkyl or heterocyclic radicals;

Wherein said alkyl; aryl; heteroaryl; cycloalkyl or heterocyclic radical can not be substituted separately, or optional independent be selected from following part and replace by one or more: hydroxyl; alkoxyl group; aryloxy; thio group; alkylthio; arylthio; amino; amido; alkylamino; arylamino; alkyl sulphonyl; aryl sulfonyl; sulfonamido; alkyl; aryl; heteroaryl; alkyl sulfonyl amino; Arenesulfonyl amino; ketone group; carboxyl; carbalkoxy; carboxamido; alkoxycarbonyl amido; alkoxycarbonyloxy; the alkyl urea groups; aryl-ureido; halogen; cyano group and nitro.

Above statement " A and M are connected to each other, so that with part shown in the following formula I:

Form 3 yuan, 4 yuan, 6 yuan, 7 yuan or 8 yuan of cycloalkyl, 4 yuan of-8 yuan of heterocyclic radicals, 6 yuan of-10 yuan of aryl or 5 yuan of-10 yuan of heteroaryls " can be described as follows by the indefiniteness mode.Therefore, for example be connected with M as A, so that with part shown in the following formula I:

Form in 6 yuan of cycloalkyl (cyclohexyl) situation,

Formula I can be described as:

Those of ordinary skills will appreciate that, as A and the M shown in the above-mentioned part:

When (M-L-E-A combines) is connected to form 3 yuan, 4 yuan, 7 yuan or 8 yuan of cycloalkyl, 4 yuan of-8 yuan of heterocyclic radicals, 6 yuan of-10 yuan of aryl or 5 yuan of-10 yuan of heteroaryls, can obtain similar description to formula I.

At above-mentioned R, R ', R ²And R ³Definition in, preferred alkyl is made up of 1-10 carbon atom, preferred alkenyl or alkynyl is made up of 2-10 carbon atom, and preferred cycloalkyl is made up of 3-8 carbon atom, and preferably assorted alkyl, heteroaryl or Heterocyclylalkyl (heterocyclic radical) have 1-6 oxygen, nitrogen, sulphur or phosphorus atom.

The compound itself of formula I representative or can be used for treating disease, for example HCV, HIV, AIDS (acquired immune deficiency syndrome (AIDS)) and relative disease with one or more other suitable drug regimen disclosed herein; And be used to regulate hepatitis C virus (HCV) protease activity, prevention HCV or alleviate one or more hepatitis C symptoms.Available The compounds of this invention carries out this adjusting, treatment, prevention or alleviation with the medicinal compositions or the preparation that contain this compounds.Bound by theory does not think that HCV proteolytic enzyme may be NS3 or NS4a proteolytic enzyme.The compounds of this invention can suppress this proteolytic enzyme.They also can regulate the processing of hepatitis C virus (HCV) polypeptide.

Describe in detail

In one embodiment, the present invention open compound or its pharmacy acceptable salt, solvate or ester by structural formula I representative, wherein the various piece definition is the same.

In another embodiment, R ¹Be NR ⁹R ¹⁰, R ⁹Be H, R ¹⁰Be H or R ¹⁴, R wherein ¹⁴Be H, alkyl, aryl, assorted alkyl, heteroaryl, cycloalkyl, alkyl-aryl, alkyl-heteroaryl, aryl-alkyl, thiazolinyl, alkynyl or heteroaryl-alkyl.

In another embodiment, R ¹⁴Be selected from:

In another embodiment, R ²Be selected from the lower section:

In a further embodiment, R ³Be selected from:

R wherein ³¹Be OH or O-alkyl; With

R ³²Be H, C (O) CH ₃, C (O) OtBu or C (O) N (H) tBu.

In another embodiment, R ³Be selected from the lower section:

In going back another embodiment, G is NH.

In a further embodiment, Y is selected from the lower section:

Y wherein ³²Be selected from:

Y ³⁰Be selected from:

Wherein u is numerical value 0-1;

And R ¹⁹Be selected from H, alkyl, phenyl or benzyl.

In going back another embodiment, T ₁And T ₂Can be identical or different, independently be selected from separately:

Or part:

Representative combines

And T ₃Be selected from:

In going back another embodiment, part:

Be selected from following structure:

In a further embodiment, part:

Be selected from following structure:

In a further embodiment, part:

Be selected from following structure:

In going back another embodiment, R ¹Be NHR ¹⁴, R wherein ¹⁴Be selected from:

R ²Be selected from the lower section:

R ³Be selected from the lower section:

Y ³⁰Be selected from:

Y wherein ³⁰Also be selected from:

Y wherein ³⁰Also be selected from:

Y ³²Be selected from:

And Y ¹²Be selected from: H, CO ₂H, CO ₂Me, OMe, F, Cl, Br, NH ₂, N (H) S (O ₂) CH ₃, N (H) C (O) CH ₃, NO ₂, NMe ₂, S (O ₂) NH ₂, CF ₃, Me, OH, OCF ₃And C (O) NH ₂

Y ³³Be selected from:

And T ₃Be selected from:

And part:

For:

Also another embodiment of the present invention is disclosed in compound shown in table 1, the back table 2.Show also in the table 2 that the biological activity of several The compounds of this invention is (as Ki ^*Value).

Table 1

Unless otherwise indicated, otherwise the following term that openly uses in full in above and the present invention is interpreted as having following implication:

" patient " comprise humans and animals both.

" Mammals " expression people and other Mammals.

" alkyl " expression can be for containing about 1 aliphatic hydrocarbyl to about 20 carbon atoms in straight or branched and the chain.Contain about 1 to about 12 carbon atoms in the preferred alkyl chain.Contain about 1 in the preferred alkyl chain to about 6 carbon atoms.Side chain is represented one or more low alkyl groups, and for example methyl, ethyl or propyl group are connected with linear alkyl chain." low alkyl group " expression have in the chain about 1 to about 6 carbon atoms, can be the group of straight or branched.Term " substituted alkyl " expression alkyl can be replaced by one or more substituting groups that can be identical or different, each substituting group independently be selected from halogen, alkyl, aryl, cycloalkyl, cyano group, hydroxyl, alkoxyl group, alkylthio, amino ,-NH (alkyl) ,-NH (cycloalkyl) ,-N (alkyl) ₂,-N (alkyl) ₂, carboxyl and-C (O) O-alkyl.The non-limiting example of suitable alkyl comprises methyl, ethyl, n-propyl, sec.-propyl and the tertiary butyl.

" thiazolinyl " expression contains the aliphatic hydrocarbyl of at least one carbon-to-carbon double bond, and it can be straight or branched, and contains about 2 in the chain to about 15 carbon atoms.Have about 2 to about 12 carbon atoms in the preferred alkenylene chain; More preferably in the chain about 2 to about 6 carbon atoms.Side chain is represented one or more low alkyl groups, and for example methyl, ethyl or propyl group are connected with the straight-chain alkenyl chain.About 2 to about 6 carbon atoms in " low-grade alkenyl " expression chain, and it can be straight or branched.Term " substituted alkenyl " expression can be by one or more thiazolinyls of replacing of substituting group that can be identical or different, and each substituting group independently is selected from following group: halogen, alkyl, aryl, cycloalkyl, cyano group, alkoxyl group and-S (alkyl).The non-limiting example of suitable thiazolinyl comprises vinyl, propenyl, n-butene base, 3-methyl but-2-ene base, positive pentenyl, octenyl and decene base.

" alkynyl " expression contains the aliphatic hydrocarbyl of at least one carbon-to-carbon triple bond, and it can be straight or branched, and contains about 2 in the chain to about 15 carbon atoms.Have about 2 to about 12 carbon atoms in the preferred alkynyl chain; More preferably in the chain about 2 to about 4 carbon atoms.Side chain is represented one or more low alkyl groups, and for example methyl, ethyl or propyl group are connected with the straight-chain alkynyl chain.About 2 to about 6 carbon atoms in " low-grade alkynyl " expression chain, and it can be straight or branched.The non-limiting example of suitable alkynyl comprises ethynyl, proyl, 2-butyne base and 3-methyl butynyl.Term " substituted alkynyl " expression can be by the alkynyl of one or more substituting group replacements that can be identical or different, and each substituting group independently is selected from following group: alkyl, aryl and cycloalkyl.

" aryl " expression contains about 6 to about 14 carbon atoms, and preferred about 6 to the aromatic monocyclic of about 10 carbon atoms or encircle loop systems more.Aryl can be chosen wantonly by one or more " loop systems substituting groups " definition, can be identical or different herein and replace.The non-limiting example of suitable aryl comprises phenyl and naphthyl.

" heteroaryl " expression contains about 5 to about 14 annular atomses, and preferred about 5 to the aromatic monocyclic of about 10 annular atomses or encircle loop systems more, and wherein one or more annular atomses are non-carbon, the combination of for example independent nitrogen, oxygen or sulphur or nitrogen, oxygen or sulphur.Preferred heteroaryl contains about 5 to about 6 annular atomses." heteroaryl " can be chosen wantonly by one or more " loop systems substituting groups " definition, can be identical or different herein and replace.Prefix azepine, oxa-or thia before the heteroaryl root name represent to exist at least one nitrogen, oxygen or sulphur atom annular atoms respectively.The nitrogen-atoms of heteroaryl can be chosen wantonly and be oxidized to corresponding N-oxide compound.The non-limiting example of suitable heteroaryl comprises pyridyl, pyrazinyl, furyl, thienyl, pyrimidyl, pyridone (comprising the pyridone that N-replaces) group, different  azoles base, isothiazolyl,  azoles base, thiazolyl, pyrazolyl, the furazan base, pyrryl, pyrazolyl, triazolyl, 1,2, the 4-thiadiazolyl group, pyrazinyl, pyridazinyl, quinoxalinyl, 2, the 3-phthalazinyl, the oxindole base, imidazo [1,2-a] pyridyl, imidazo [2,1-b] thiazolyl, benzo furazan base, indyl, azaindolyl, benzimidazolyl-, benzothienyl, quinolyl, imidazolyl, the thienopyridine base, quinazolyl, the Thienopyrimidine base, pyrrolopyridinyl, imidazopyridyl, isoquinolyl, the benzo-aza indyl, 1,2, the 4-triazinyl, benzothiazolyl etc.Term " heteroaryl " also divides saturated heteroaryl moieties, for example tetrahydro isoquinolyl, tetrahydric quinoline group etc. in the finger.

" aralkyl " or " arylalkyl " expression aryl-alkyl-, wherein aryl and alkyl are with aforementioned.Preferred aralkyl comprises low alkyl group.The non-limiting example of suitable aralkyl comprises benzyl, 2-styroyl and naphthyl methyl.Be connected with nucleus part by alkyl.

" alkaryl " expression alkyl-aryl-, wherein alkyl and aryl are with aforementioned.Preferred alkaryl comprises low alkyl group.The non-limiting example of suitable alkaryl has tolyl.Be connected with nucleus part by aryl.

" cycloalkyl " expression contains about 3 to the non-aromatic monocyclic of about 10 carbon atoms or encircle loop systems more, and preferred about 5 to about 10 carbon atoms.Preferred cycloalkyl ring contains about 5 to about 7 annular atomses.Cycloalkyl can be chosen wantonly by one or more definition " loop systems substituting group " the same, can be identical or different and replace.The non-limiting example of suitable monocyclic cycloalkyl comprises cyclopropyl, cyclopentyl, cyclohexyl, suberyl etc.The non-limiting example of suitable polycyclic naphthene base comprises the polycyclic naphthene base of 1-naphthalane base, norborneol alkyl (norbornyl), adamantyl (adamantyl) etc. and fractional saturation, for example 2,3 indanyls, tetrahydro naphthyl etc.

" halogen " expression fluorine, chlorine, bromine or iodine.Preferred fluorine, chlorine and bromine.

The substituting group that " loop systems substituting group " expression is connected with aromatics or non-aromatics loop systems, it is the available hydrogen in the D-loop system for example.The loop systems substituting group can be identical or different, independently is selected from alkyl separately; thiazolinyl; alkynyl; aryl; heteroaryl; aralkyl; alkylaryl; heteroaralkyl; the heteroaryl thiazolinyl; the heteroaryl alkynyl; miscellaneous alkyl aryl; hydroxyl; hydroxyalkyl; alkoxyl group; aryloxy; aralkoxy; acyl group; aroyl; halogen; nitro; cyano group; carboxyl; carbalkoxy; aryloxycarbonyl; aromatic alkoxy carbonyl; alkyl sulphonyl; aryl sulfonyl; heteroarylsulfonyl; alkylthio; arylthio; heteroarylthio; aromatic alkylthio; assorted aromatic alkylthio; cycloalkyl; heterocyclic radical;-C (=N-CN)-NH ₂,-C (=NH)-NH ₂,-C (=NH)-NH (alkyl), Y ₁Y ₂N-, Y ₁Y ₂The N-alkyl-, Y ₁Y ₂NC (O)-, Y ₁Y ₂NSO ₂-and-SO ₂NY ₁Y ₂, Y wherein ₁And Y ₂Can be identical or different, and independently be selected from hydrogen, alkyl, aryl, cycloalkyl and aralkyl." loop systems substituting group " also can represent in the D-loop system simultaneously a part of two available hydrogen (1 H on each carbon) on the two adjacent carbon atoms.The example of this part be methylene-dioxy, ethylenedioxy ,-C (CH ₃) ₂-etc., it forms part, for example:

" heterocyclic radical " expression contains about 3 to about 10 annular atomses, preferred about 5 to the non-aromatics saturated mono ring of about 10 annular atomses or encircle loop systems more, wherein the one or more atoms in the loop systems are non-carbon, the combination of for example independent nitrogen, oxygen or sulphur or nitrogen, oxygen or sulphur.There are not adjacent oxygen and/or sulphur atom in the loop systems.Preferred heterocyclic radical contains about 5 to about 6 annular atomses.Prefix azepine, oxa-or thia before the heterocyclic radical root name represent to exist at least one nitrogen, oxygen or sulphur atom annular atoms respectively.Can there be blocking group in any-NH in the heterocyclic ring, for example-N (Boc) ,-N (CBz) ,-N (Tos) group etc.; Also this type of protection can be considered as a part of the present invention.Heterocyclic radical can be chosen wantonly by one or more " loop systems substituting groups " definition, can be identical or different herein and replace, and nitrogen or the oxidized sulfur atom that can choose wantonly heterocyclic radical are corresponding N-oxide compound, S-oxide compound or S, the S-dioxide.The non-limiting example of suitable monocyclic heterocycles basic ring comprises piperidyl, pyrrolidyl, piperazinyl, morpholinyl, thio-morpholinyl, thiazolidyl, 1,4-two  alkyl, tetrahydrofuran base, tetrahydro-thienyl, lactam group, lactone group etc.

It should be noted that in containing heteroatomic loop systems of the present invention do not have hydroxyl on the carbon atom adjacent, and do not have N or S base on the carbon adjacent with another heteroatoms with N, O or S.Therefore, for example on following ring:

Not with the carbon of mark 2 and 5 direct-connected-OH.

It shall yet further be noted that and think tautomeric form, for example with the lower section:

Be equal in certain embodiments of the invention.

" alkynyl alkyl " expression alkynyl-alkyl-, wherein alkynyl and alkyl are with aforementioned.Preferred alkynyl alkyl contains low-grade alkynyl and low alkyl group.Be connected with nucleus part by alkyl.The non-limiting example of suitable alkynyl alkyl comprises the propargyl methyl.

" heteroaralkyl " expression heteroaryl-alkyl-, wherein heteroaryl and alkyl are with aforementioned.Preferred heteroaralkyl contains low alkyl group.The non-limiting example of suitable aralkyl comprises pyridylmethyl and quinoline-3-ylmethyl.Be connected with nucleus part by alkyl.

" hydroxyalkyl " expression HO-alkyl-, wherein the alkyl definition is the same.Preferred hydroxyalkyl contains low alkyl group.The non-limiting example of suitable hydroxyalkyl comprises methylol and 2-hydroxyethyl.

" acyl group " expression H-C (O)-, alkyl-C (O)-or cycloalkyl-C (O)-group, wherein various groups are with aforementioned.Be connected with nucleus part by carbonyl.Preferred acyl group contains low alkyl group.The non-limiting example of suitable acyl group comprises formyl radical, ethanoyl and propionyl.

" aroyl " expression aryl-C (O)-group, wherein aryl is with aforementioned.Be connected with nucleus part by carbonyl.The non-limiting example of suitable group comprises benzoyl and 1-naphthoyl.

" alkoxyl group " expression alkyl-O-group, wherein alkyl is with aforementioned.The non-limiting example of suitable alkoxyl group comprises methoxyl group, oxyethyl group, positive propoxy, isopropoxy and n-butoxy.Be connected with nucleus part by ether oxygen.

" aryloxy " expression aryl-O-group, wherein aryl is with aforementioned.The non-limiting example of suitable aryloxy comprises phenoxy group and naphthyloxy.Be connected with nucleus part by ether oxygen.

" aralkoxy " expression aralkyl-O-group, wherein aralkyl is with aforementioned.The non-limiting example of suitable aralkoxy comprises benzyloxy and 1-or 2-naphthalene methoxyl group.Be connected with nucleus part by ether oxygen.

" alkylthio " expression alkyl-S-group, wherein alkyl is with aforementioned.The non-limiting example of suitable alkylthio comprises methylthio group and ethylmercapto group.Be connected with nucleus part by sulphur.

" arylthio " expression aryl-S-group, wherein aryl is with aforementioned.The non-limiting example of suitable arylthio comprises thiophenyl and naphthalene sulfenyl.Be connected with nucleus part by sulphur.

" aromatic alkylthio " expression aralkyl-S-group, wherein aralkyl is with aforementioned.The non-limiting example of suitable aromatic alkylthio is a benzylthio-.Be connected with nucleus part by sulphur.

" carbalkoxy " expression alkyl-O-CO-group.The non-limiting example of suitable carbalkoxy comprises methoxycarbonyl and ethoxy carbonyl.Be connected with nucleus part by carbonyl.

" aryloxycarbonyl " expression aryl-O-C (O)-group.The non-limiting example of suitable aryloxycarbonyl comprises phenyloxycarbonyl and naphthyloxy carbonyl.Be connected with nucleus part by carbonyl.

" aromatic alkoxy carbonyl " expression aralkyl-O-C (O)-group.The non-limiting example of suitable aromatic alkoxy carbonyl is a benzyloxycarbonyl.Be connected with nucleus part by carbonyl.

" alkyl sulphonyl " expression alkyl-S (O ₂)-group.Preferred group is that wherein alkyl is those groups of low alkyl group.Be connected with nucleus part by alkylsulfonyl.

" aryl sulfonyl " expression aryl-S (O ₂)-group.Be connected with nucleus part by alkylsulfonyl.

Term " replacement " is illustrated in one or more hydrogen on the specified atom by the group displacement of selecting from specify group, condition be there is something special down, do not exceed the normal valency of specified atom, and this replacement causes stable compound.As long as this type of combination results stable compound just allows the combination of substituting group and/or variable." stable compound " or " rock steady structure " expression is enough stable, can separate effective purity and be mixed with the compound of effective medicine from reaction mixture.

When indicating the number of substituting group, compound, combination medicine etc., based on context term " a kind of (individual) or multiple (individual) " or " at least a (individual) " refer to, exist or add at least a (individual) and be up to the chemistry of maximum number and the substituting group of permission physically, compound, combination medicine etc., relevant technologies personnel know this type of technology and knowledge.

Term " the optional replacement " expression replaces with special groups, atomic group or part are optional.

The term " separation " or " unpack format " that are used for compound refer to after building-up process or natural origin or its combination separation the physical condition of described compound.After being used for the term " purifying " of compound or " purified form " and referring to be obtained by the treatment process that purification treating method or treatment process described herein or those of skill in the art know, purity is enough to the physical condition of the described compound that characterizes by the standard analytical techniques that described or those of skill in the art herein know.

It shall yet further be noted that supposition has any heteroatoms of unsaturated valency in this paper text, flow process, embodiment and Biao, have the hydrogen atom that makes valency saturated.

When the functional group in the compound was called " protection ", this represented that this group is a modified forms, when the reaction of compound experience, can get rid of unwanted side reaction at the protection position.Those of ordinary skills and by the reference standard teaching material, T.W.Greene etc. for example, Protective Groups in organic Synthesis (1991), Wiley, New York can determine suitable blocking group.

As any variable (for example aryl, heterocycle, R ²Deng) when occurring greater than one time at any composition or in formula I, its definition when at every turn occurring is independent of its definition in every other appearance.

Term used herein " composition " will comprise the product of the appointment composition that contains specified amount and any product that is directly or indirectly produced by the combination of the appointment composition of specified amount.

The prodrug and the solvate of The compounds of this invention are also included within herein.Term used herein " prodrug " is expressed as the compound of prodrug, after this precursor gives the patient, carries out chemical conversion by metabolism or chemical process, production I compound or its salt and/or solvate.At T.Higuchi and V.Stella, Pro-drugs as Novel Delivery Systems (1987) 14, the A.C.S.Symposium Series and at Bioreversible Carriers inDrug Design, (1987) Edward B.Roche edits, the argumentation of prodrug is provided among the American PharmaceuticalAssociation and Pergamon Press, and these two pieces of documents are attached to herein by reference.

The physics associated complex of " solvate " expression The compounds of this invention and a plurality of solvent molecules.This physics associates and relates to ion in various degree and the covalent bonding that comprises hydrogen bonding.In some cases, for example when one or more solvent molecules are bonded in the lattice of crystalline solid, solvate can be separated." solvate " comprises solution phase and separable solvate.The non-limiting example of suitable solvate comprises ethylate, methylate etc." hydrate " is H for solvent molecule wherein ₂The solvate of O.

" significant quantity " or " treatment significant quantity " is used to describe effective inhibition CDK (s), and therefore produces the The compounds of this invention of the treatment, alleviation, inhibition or the prophylactic effect that need or the amount of composition.

Formula I compound can form also salt within the scope of the present invention.Should be understood that unless otherwise indicated, comprise and relate to its salt otherwise relate to this paper Chinese style I compound.Term used herein " salt " expression is by inorganic and/or acid salt that organic acid forms with by subsalt inorganic and/or that organic bases forms.In addition, when formula I compound had both contained basic moiety such as but not limited to pyridine or imidazoles, when containing the acidic moiety such as but not limited to carboxylic acid again, zwitter-ion (" inner salt ") can form, and is included in the term used herein " salt ".Preferably pharmaceutically acceptable (promptly nontoxic, physiologically acceptable) salt is although other salt is also effective.For example, can be by making formula I compound at medium, the sedimentary medium of salt or in aqueous medium, with the acid or the alkali reaction of a certain amount of for example monovalent, freeze-drying subsequently forms the salt of formula I compound therein for example.

The exemplary acids additive salt comprises acetate, ascorbate salt, benzoate, benzene sulfonate, hydrosulfate, borate, butyrates, Citrate trianion, camphorate, camsilate, fumarate, hydrochloride, hydrobromate, hydriodate, lactic acid salt, maleate, mesylate, naphthalenesulfonate, nitrate, oxalate, phosphoric acid salt, propionic salt, salicylate, succinate, vitriol, tartrate, thiocyanate-, tosylate (being called tosylate again) etc.In addition, P.Stahl etc. for example, Camille G. (editor) Handbook ofPharmaceutical Salts.Properties, Selection and Use. (2002) Zurich:Wiley-VCH; S.Berge etc., Journal of Pharmaceutical Sciences (1977) 66 (1) 1-19; P.Gould, International J.of Pharmaceutics (1986) 33 201-217; Anderson etc., The Practice of Medicinal Chemistry (1996), AcademicPress, New York; With at The Orange Book (Food ﹠amp; Drug Administration, Washington, D.C. is on its website) discussed and it has been generally acknowledged that and be applicable to the acid that forms basic medicinally compound pharmaceutical salts.These disclosures are attached to herein by reference.

Exemplary basic salts comprises ammonium salt; An alkali metal salt, for example sodium, lithium and sylvite; Alkaline earth salt, for example calcium and magnesium salts; Organic bases (for example organic amine), for example salt of dicyclohexyl amine, TERTIARY BUTYL AMINE and amino acid, for example salt of arginine, Methionin etc.Available for example elementary alkyl halide (for example muriate of methyl, ethyl and butyl, bromide and iodide), sulfuric acid dialkyl (for example methyl-sulfate, diethyl ester and dibutylester), long-chain halogenide (for example muriate, bromide and the iodide of decyl, dodecyl and hard ester acyl group), aralkyl halide (for example bromotoluene and phenethyl bromide) and other reagent make alkaline nitrogen-containing group quaternized.

All these type of acid salt and subsalt all should be the pharmacy acceptable salt in the scope of the invention, are the object of the invention, and all acid salt and subsalt are considered as the equivalent of respective compound free form.

The pharmaceutically acceptable ester of The compounds of this invention comprises following ester class: (1) carboxylicesters by hydroxy esterification is obtained, wherein the non-carbonyl moiety of the carboxylic moiety of ester is selected from straight or branched alkyl (for example ethanoyl, n-propyl, the tertiary butyl or normal-butyl), alkoxyalkyl (for example methoxymethyl), aralkyl (for example benzyl), aryloxy alkyl (for example phenoxymethyl), (for example optional quilt is halogen, C for example for aryl _1-4Alkyl or C _1-4Alkoxyl group or the amino phenyl that replaces); (2) sulphonate, for example alkyl-or aralkyl alkylsulfonyl (for example methylsulfonyl); (3) amino acid ester (for example L-is valyl or the L-isoleucyl); (4) phosphonic acid ester and (5)-, two-or triguaiacyl phosphate.Can be by for example C _1-20Alcohol or its reactive derivative, or by 2,3-two (C _6-24) acylglycerol makes the further esterification of phosphoric acid ester.

Can their tautomeric form there be (for example acid amides or imino-ether) in formula I compound and salt thereof, solvate, ester and prodrug.Expectation with all these type of tautomeric forms as a part of the present invention.

All steric isomers of The compounds of this invention (for example geometrical isomer, optically active isomer etc.) (those steric isomers that comprise salt, solvate and the prodrug of these compounds, and the steric isomer of the salt of prodrug and solvate), for example because the asymmetric carbon on each substituting group and those steric isomers that may exist, comprise that enantiomorph is not (when even existing asymmetric carbon, it also may exist), rotational isomer, atropisomer and diastereomer, be included in the scope of the present invention as positional isomers (for example 4-pyridyl and 3-pyridyl).Each steric isomer of The compounds of this invention can for example be substantially free of other isomer, or can mix with the steric isomer of all other steric isomers or other selection, for example racemic modification.Chiral centre of the present invention can have the S or the R configuration of IUPAC 1974 Recommendations definition.The purposes of term " salt ", " solvate " " prodrug " etc. will be applied to salt, solvate and the prodrug of enantiomorph, steric isomer, rotational isomer, tautomer, positional isomers, racemic modification or the prodrug of The compounds of this invention equally.

Salt, solvate, ester and the prodrug of the polymorphic of formula I compound and formula I compound will comprise in the present invention.

Should be understood that the effectiveness of the formula I compound of the treatment application that is used for discussing herein, applicable to one or more combinations of each compound itself or one or more formulas I compound, as in being right after next section, setting forth.Same understanding also is applicable to the medicinal compositions that contains one or more such compounds and relates to the methods of treatment of one or more such compounds.

The compounds of this invention can have pharmacological properties; Especially formula I compound can be the HCV proteinase inhibitor, and each compound itself or one or more formulas I compound can make up with one or more compounds that are selected from the formula I scope.This compounds can be used for treating disease, for example HCV, HIV, (AIDS, acquired immune deficiency syndrome (AIDS)) and relative disease; And adjusting hepatitis C virus (HCV) protease activity; Prevent HCV or alleviate one or more hepatitis C symptoms.

Formula I compound can be used for preparing the medicine that is used for the treatment of with HCV proteolytic enzyme diseases related, for example, comprises the method that formula I compound and pharmaceutically acceptable carrier are fully contacted.

In another embodiment, the invention provides and contain the medicinal compositions of one or more The compounds of this invention as activeconstituents.Medicinal compositions also contains at least a pharmaceutically acceptable carrier thinner, vehicle or carrier (being referred to as carrier substance herein) usually.Because it is active that their HCV suppresses, this type of medicinal compositions has the effectiveness of treatment hepatitis C and relative disease.

In going back another embodiment, the present invention openly prepares and contains the method for The compounds of this invention as the medicinal compositions of activeconstituents.In medicinal compositions of the present invention and method, the general mixing with the suitable carriers material of activeconstituents gives, these carrier substance carry out appropriate selection according to following predetermined form of medication: promptly oral tablet, capsule (solid is filled, the semi-solid filling or liquid filling) but, dissolving is with powder, oral gel, elixir dispersible granule, syrup, suspension etc., and meets the conventional pharmaceutical practice.For example, for tablet or capsule form of medication, can make active pharmaceutical ingredient and any oral, nontoxic pharmaceutically acceptable inert support, for example lactose, starch, sucrose, Mierocrystalline cellulose, Magnesium Stearate, Lin Suanergai, calcium sulfate, talcum powder, N.F,USP MANNITOL, ethanol mixing such as (liquid forms).In addition, when needs or in case of necessity, also suitable binder, lubricant, disintegrating agent and tinting material can be mixed in this mixture.The present composition accounts for about 5% to about 95% in powder and the tablet.

Suitable binder comprises starch, gelatin, natural sugar, corn sweetener, natural and synthetical glue for example gum arabic, sodiun alginate, carboxymethyl cellulose, polyoxyethylene glycol and wax.In lubricant, can mention be used for these formulations boric acid, Sodium Benzoate, sodium acetate, sodium-chlor etc. are arranged.Disintegrating agent comprises starch, methylcellulose gum, melon glue etc.

In the time of suitably, also can comprise sweeting agent, correctives and sanitas.Below discuss more above-mentioned terms in more detail, i.e. disintegrating agent, thinner, lubricant, tackiness agent etc.

In addition, the present composition can be mixed with the slowly-releasing form, and so that the controlled release speed of any or various ingredients or activeconstituents to be provided, making therapeutic action is that HCV suppresses optimizings such as activity.Suitable slow release formulation comprises layergram, and this layergram contains different disintegration rate layers or with the controlled release polymer skeleton of activity component impregnation, and is shaped to tablet; Or capsule, this capsule contains the porous polymer framework of this type of dipping or envelope capsuleization.

Liquid absorption member comprises solution, suspensoid and emulsion.As an example, the water that is useful on parenteral injection or the water-propylene glycol solution that can mention, or oral liquid, suspension and the emulsion of adding sweeting agent and tranquilizer (pacifiers).Liquid form preparation also can comprise the solution that intranasal administration is used.

The aerosol formulation that is applicable to suction can comprise the solid of solution and powder type, it can with pharmaceutically acceptable carrier, for example for example nitrogen combination of inertia pressurized gas.

Be preparation suppository, earlier with low melt wax, for example for example theobroma oil fusing of the mixture of glycerin fatty acid ester, with activeconstituents by stirring or similarly mixing dispersion wherein.Then, in the mould of uniform mixture impouring suitable size with fusing, make its cooling and therefore solidify.

Also comprise predetermined facing with the solid form preparation that before is converted into the liquid form preparation that is used for oral or administered parenterally.This type of liquid form comprises solution, suspension and emulsion.

But The compounds of this invention is transdermal release also.Transdermal composition can adopt the form of ointment, lotion, aerosol and/or emulsion, and can be included in the transdermal patch of skeleton or bank type, and this is the conventional means that is used for this purpose.

But also in the per os, intravenously, nose or the subcutaneous The compounds of this invention that gives.

The compounds of this invention also can comprise the preparation of unit dosage.In this form, preparation can be further divided into and contain appropriate amount, for example reach the unitary dose of suitable size of the active ingredient of the significant quantity that needs purpose.

The amount of the active composition of the present invention in unit dose formulations usually can be different, or can be according to concrete application, at about 1.0mg to about 1,000mg, preferred about 1.0 to about 950mg, more preferably from about 1.0 to about 500mg, common about 1 to about 250mg range regulation.The actual dosage that uses can change according to patient's age, sex, body weight and the disease serious degree of being treated.Those skilled in the art know this type of technology.

Usually, but the human oral formulation that contains activeconstituents give 1 or 2 time every day.Dosage and frequency are regulated in judgement by the attending doctor.Usually the oral administration per daily dose scheme of recommending can be by single dose or divided dose, and every day, about 1.0mg was extremely about 1,000mg.

Some useful term is below described:

Special container or shell that capsule-refer to is made by methylcellulose gum, polyvinyl alcohol or metagelatin or starch are used to hold or comprise and contain composition of active components.Hard-shell capsule is made by the mixture of relative high-gel strength bone and pigskin gelatin usually.Capsule itself can contain a small amount of dyestuff, opalizer, softening agent and sanitas.

Tablet-refer to the contain compacting or the molded solid formulation of activeconstituents and suitable diluents.Can prepare tablet by pressing mixt or by wet granulation, dry granulation or by the particle that compression obtains.

Oral gel-refer to is dispersed in or is dissolved in activeconstituents in the wetting ability semisolid matrix.

Dissolving refers to be suspended in the powdered mixture that contains activeconstituents and suitable diluents in water or the fruit juice with powder.

Thinner-refer to constitute the usually material of composition or formulation major portion.Suitable diluent comprises sugar, for example lactose, sucrose, N.F,USP MANNITOL and sorbyl alcohol; Be derived from the starch of wheat, corn, rice and potato; And Mierocrystalline cellulose, for example Microcrystalline Cellulose.The amount of thinner can account for composition gross weight about 10% to about 90% (weight) in the composition, and preferred about 25% to about 75%, and more preferably from about 30% to about 60% (weight), even more preferably from about 12% to about 60%.

Disintegrating agent-refer to add composition helps its fragmentation (disintegration) and discharges the material of medicine.Suitable disintegrants comprises starch; " coldwater-soluble " treated starch, for example sodium starch glycolate; Natural and synthetical glue, for example tracasol, kuteera gum, guar gum, tragacanth and agar; Derivatived cellulose, for example methylcellulose gum and Xylo-Mucine; Microcrystalline Cellulose and crosslinked Microcrystalline Cellulose, for example croscarmellose sodium; Alginate, for example alginic acid and sodiun alginate; Clay, for example wilkinite; And effervescent mixture.Disintegration dosage can account for composition about 2% to about 15% (weight) in the composition, and more preferably from about 4% to about 10% (weight).

Tackiness agent-refer to is by forming particle, with powder-stuck or " gummed " together and make the material that they bond together, so is used as " binding agent " in preparation.Tackiness agent increases existing cohesive strength in thinner or the extender.Suitable binder comprises sugar, for example sucrose; Be derived from the starch of wheat, corn, rice and potato; Natural gum, for example gum arabic, gelatin and tragacanth; Marine alga derivative, for example alginic acid, sodiun alginate and ammonium alginate calcium; Cellulose substances, for example methylcellulose gum and Xylo-Mucine and Vltra tears; Polyvinylpyrrolidone; And inorganics, for example neusilin.The amount of tackiness agent can account for composition about 2% to about 20% (weight) in the composition, and more preferably from about 3% to about 10% (weight), even more preferably from about 3% to about 6% (weight).

Lubricant-refer to add in the formulation, by reducing friction or wearing and tearing, the tablet after guaranteeing to suppress, particle etc. are from the material of mould or punch die release.Examples of suitable lubricants comprises metallic stearate, for example Magnesium Stearate, calcium stearate or potassium stearate; Stearic acid; High melting-point wax; And soluble oil, for example sodium-chlor, Sodium Benzoate, sodium acetate, sodium oleate, polyoxyethylene glycol and d ' l-leucine.The lubricant very back step before compacting usually adds, because they must be present between particle surface, the particle and on the part tabletting machine.The amount of lubricant can account for composition about 0.2% to about 5% (weight) in the composition, and preferred about 0.5% to about 2%, and more preferably from about 0.3% to about 1.5% (weight).

Glidant-prevent particle bond and improve mobility of particle is so that flow level and smooth and uniform material.Suitable glidant comprises silicon-dioxide and talcum powder.The amount of glidant can account for total composition about 0.1% to about 5% (weight) in the composition, and preferred about 0.5% to about 2% (weight).

Tinting material-the vehicle of color is provided for composition or formulation.This type of vehicle can comprise and be adsorbed on suitable adsorbent, for example one or more food grade dyestuffs on clay or the aluminum oxide.The amount of tinting material can account for composition about 0.1% to about 5% (weight), and preferred about 0.1% to about 1%.

Bioavailability-refer to compare with standard substance or reference substance absorbs the active pharmaceutical ingredient of the recycle system or the speed and the degree of treatment part from form of administration.

The ordinary method of known preparation tablet.These class methods comprise dry method, and for example directly the particle that compression prepares is passed through in compacting and compacting, or wet method or other special methods.Also know preparation other form of medication, for example ordinary method of capsule, suppository etc.

Open above disclosed The compounds of this invention of another embodiment of the present invention or medicinal compositions treatment disease, for example purposes of hepatitis C etc.This method comprises the The compounds of this invention or the medicinal compositions of the patient treatment significant quantity of suffering from this disease or this class disease and this treatment of needs.

In another embodiment also, can be by monotherapy pattern or conjoint therapy (for example bigeminy, three etc.), for example with pattern antiviral and/or the immunomodulator associating, with The compounds of this invention treatment people HCV.This class example antiviral and/or immunomodulator comprises ribavirin (coming from Schering-Plough Corporation, Madison, New Jersey) and Levovirin ^TM(come from ICN Pharmaceuticals, Costa Mesa, California), VP50406 ^TM(come from Viropharma, Incorporated, Exton, Pennsylvania); ISIS14803 ^TM(come from ISIS Pharmaceuticals, Carlsbad, California); Heptazyme ^TM(come from Ribozyme Pharmaceuticals, Boulder, Colorado); VX 497 ^TM(come from Vertex Pharmaceuticals, Cambridge, Massachusetts); Thymosin ^TM(come from SciClone Pharmaceuticals, San Mateo, California); Maxamine ^TM(MaximPharmaceuticals, San Diego, California); Mycophenolate mofetil (coming from Hoffman-LaRoche, Nutley, New Jersey); Interferon, rabbit (for example alpha-interferon, PEG-alpha-interferon conjugates) etc." PEG-alpha-interferon conjugates " is the alpha-interferon molecule covalently bound with the PEG molecule.Exemplary PEG-alpha-interferon conjugates comprises that the α-2a forms of interferon of Pegylation is (for example with trade(brand)name Pegasys ^TMSale) α-2a Interferon, rabbit (Roferon ^TM, come from Hoffman La-Roche, Nutley, New Jersey), the α-2b forms of interferon of Pegylation is (for example with trade(brand)name PEG-Intron ^TMSale) α-2b Interferon, rabbit (Intron ^TM, come from Schering-Plough Corporation); α-2c Interferon, rabbit (BeroforAlpha ^TM, come from Boehringer Ingelheim, Ingelheim, Germany) or the IFN-con (Infergen of the consensus sequence definition by measuring naturally occurring alpha-interferon ^TM, come from Amgen, Thousand Oaks, California).

As previously mentioned, the present invention also comprises tautomer, rotational isomer, diastereomer, enantiomorph and other steric isomer of The compounds of this invention.Therefore, as recognized by the skilled person, may there be suitable isomeric form in some The compounds of this invention.This type of variation is included in the scope of the present invention.

Another embodiment of the present invention openly prepares the come into the open method of compound of this paper.Can prepare these compounds by technology more known in the art.Illustrated example method in following reaction process.These examples should be interpreted as restriction to the scope of the invention of claims definition.Alternate mechanism pathway and analog structure will be apparent to those skilled in the art.

Describe the preparation of some representational The compounds of this invention though should be understood that following exemplary flow, will cause forming the compound based on this replacement of needs to any natural and suitable replacement alpha-non-natural amino acid.This type of variation is included in the scope of the present invention.

Abbreviation

The abbreviation that is used to describe following flow process, preparation and embodiment has:

THF: tetrahydrofuran (THF)

DMF:N, dinethylformamide

EtOAc: ethyl acetate

AcOH: acetate

HOOBt:3-hydroxyl-1,2,3-phentriazine-4 (3H)-ketone

EDCl:1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride

The NMM:N-methylmorpholine

ADDP:1,1 '-(azo dicarbapentaborane) connection piperidines

DEAD: diethyl azodiformate

MeOH: methyl alcohol

EtOH: ethanol

Et ₂O: ether

DMSO: methyl-sulphoxide

The HOBt:N-hydroxybenzotriazole

PyBrOP: phosphofluoric acid bromo-three-pyrrolidyl 

DCM: methylene dichloride

DCC:1, the 3-dicyclohexylcarbodiimide

TEMPO:2,2,6,6-tetramethyl--piperidino oxygen base

Phg: phenylglycine

Chg: Cyclohexylglycine

Bn: benzyl

Bzl: benzyl

Et: ethyl

Ph: phenyl

IBoc; Isobutoxy carbonyl

IPr: sec.-propyl

^tBu or Bu ^t: the tertiary butyl

Boc: tert-butoxycarbonyl

Cbz: benzyloxycarbonyl

Cp: cyclopentyl dialkylene (cylcopentyldienyl)

Ts: p-toluenesulfonyl

Me: methyl

HATU: phosphofluoric acid O-(7-azepine benzo triazol-1-yl)-1,1,3,3-tetramethyl-urea 

DMAP:4-N, the N-Dimethylamino pyridine

BOP: benzotriazole-1-base-oxygen base-three (dimethylamino) hexafluorophosphate

PCC: pyridinium chlorochromate 

KHMDS: hexamethl disilamine base potassium or two (trimethyl silyl amino) are changed potassium

NaHMDS: hexamethl disilamine base sodium or two (trimethyl silyl amino) are changed sodium

LiHMDS: hexamethl disilamine base lithium or two (trimethyl silyl amino) are changed lithium

10%Pd/C:10% palladium/carbon (weight)

TG: thioglycerin

The generalized flowsheet of preparation target compound

With the synthetic The compounds of this invention of following generalized flowsheet (method A-E).

Method A:

Under acidic conditions, the N-Boc functional group deprotection with 1.01 obtains hydrochloride 1.02, uses the peptide coupling method subsequently, makes it and uncle N-Boc--leucine coupling, obtains 1.03.By handling,, obtain urea 1.05 subsequently with the N-Boc deprotection with suitable isocyanate (ester).With the methyl esters hydrolysis, obtain acid 1.06.Make acid 1.06 and suitable substance P ₁-P ' primary amide partly carries out the peptide coupling, obtains oxyamide 1.07.Oxidation (Moffatt oxidation or method-referring to T.T.Tidwell, Synthesis, 1990,857; Or Dess-Martin Periodinane-J.Org.Chem., (1983), 48,4155), obtain target compound 1.08.

Method B

Make acid 1.06 and suitable substance P ₁-P ' secondary amide partly carries out the peptide coupling, obtains oxyamide 1.09.Oxidation (Moffatt or Dess-Martin) obtains target compound 1.10.

Method C

In another kind changes, make N-Boc-P2-P ₃-acid 1.17 and suitable substance P ₁-P ' amide moieties carries out the peptide coupling, obtains oxyamide 1.11.Oxidation (Moffatt or Dess-MartinPeriodinane) obtains ketone group acid amides 1.12.Make N-Boc functional group deprotection, obtain hydrochloride 1.13.Handle with suitable isocyanate (ester) (or isocyanate (ester) equivalent), obtain target compound 1.14.

Method D

In also another kind changes,, hydrochloride 1.13 is converted into carboxylamine 4-nitro phenyl ester 1.15 by reacting with chloroformic acid 4-nitro phenyl ester.Select subsequently to handle, obtain target compound 1.14 with amine (or amine hydrochlorate).

Method E

In also another kind changes,, dipeptides hydrochloride 1.03 is converted into carboxylamine 4-nitro phenyl ester as above-mentioned.Select to handle, obtain urea derivatives 1.05 with amine (or amine hydrochlorate).By described method A/B, hydrolysis is also further handled, and obtains target compound 1.14.

Preparation P1-P ' part:

Preparation intermediate 10.11 and 10.12:

Step 1:

At N ₂Down, stir down, (50g, anhydrous THF (400mL) solution 187.1mmol) are cooled to-78 ℃, use 1M K-with ketoimine 10.01 ^tThe THF solution of BuO (220mL, 1.15 equivalents) is handled.Make reaction mixture be warming up to 0 ℃, stir 1h, (28mL 249mmol) handles with the brooethyl tetramethylene.At room temperature, reaction mixture is stirred 48h, vacuum concentration.Residue is dissolved in Et ₂O (300mL), (2M 300mL) handles with the HCl aqueous solution.At room temperature, the solution stirring 5h with obtaining uses Et ₂O (1L) extraction.With NaOH (50% aqueous solution) water layer is transferred to alkaline pH～12-14, use CH ₂Cl ₂(3 * 300mL) extractions.With the organic layer drying (MgSO that merges ₄), filter, concentrate, obtain pure amine (10.02,18g), be colorless oil.

Step 2

Under 0 ℃, with amine 10.02 (18g, CH 105.2mmol) ₂Cl ₂(350mL) (23g 105.4mmol) handles solution, at room temperature stirs 12h with two carbonic acid, two-tert-butyl ester.After reacting completely (TLC),, residue is dissolved in THF/H with the reaction mixture vacuum concentration ₂O (200ml, 1: 1) uses LiOHH ₂(6.5g 158.5mmol) handles O, at room temperature stirs 3h.Reaction mixture is concentrated, with alkaline water layer Et ₂The O extraction.Water layer is acidified to pH～1-2 with dense HCl, uses CH ₂Cl ₂Extraction.With the organic layer drying (MgSO that merges ₄), filtering, vacuum concentration obtains 10.03, is colourless viscosity oily matter, need not any being further purified and promptly can be used for next step.

Step 3

At room temperature, with acid 10.03 (15.0g, CH 62mmol) ₂Cl ₂(250ml) (41.1g, 93mmol), N-methylmorpholine (27ml), N, (9.07g 93mmol) handles the O-dimethyl hydroxylamine hydrochloride solution, and stirring is spent the night with bop reagent.Reaction mixture with the 1N HCl aqueous solution (250ml) dilution, is separated liquid layer, with water layer CH ₂Cl ₂(3 * 300ml) extractions.With the organic layer drying (MgSO that merges ₄), filtering, vacuum concentration is by chromatography (SiO ₂, EtOAc/Hex 2: 3) and purifying, obtain acid amides 10.04 (15.0g), be colorless solid.

Step 4

Under 0 ℃, drip LiAlH ₄(1M, 93mL 93mmol) handle acid amides 10.04 (15g, anhydrous THF (200mL) solution 52.1mmol) to solution.At room temperature, reaction mixture is stirred 1h, under 0 ℃, use KHSO ₄0.5h is stirred in (10% aqueous solution) careful quencher.(1M, 150mL) CH is used in dilution with the HCl aqueous solution with reaction mixture ₂Cl ₂(3 * 200mL) extractions.With the organic layer HCl aqueous solution (1M) that merges, saturated NaHCO ₃, the salt water washing, dry (MgSO ₄).Mixture is filtered, and vacuum concentration obtains 10.05, is viscosity colorless oil (14g).

Step 5

With aldehyde 10.05 (14g, CH 61.6mmol) ₂Cl ₂(50mL) solution Et ₃N (10.73mL, 74.4mmol) and acetone cyanohydrin (10.86g 127.57mmol) handles, and at room temperature stirs 24h.With the reaction mixture vacuum concentration, (1M, 200mL) dilution is extracted into CH with the HCl aqueous solution ₂Cl ₂(3 * 200mL).With the organic layer H that merges ₂O, salt water washing, dry (MgSO ₄), filtering, vacuum concentration is by chromatography (SiO ₂, EtOAc/Hex 1: 4) and purifying, obtain 10.06 (10.3g), be colourless liquid.

Step 6

Under 0 ℃, by to CH ₃Bubbling feeding HCl gas prepares HCl among the OH (700ml) ^*Saturated methyl alcohol is handled reflux 24h with it with cyanohydrin 10.06.With the reactant vacuum concentration, obtain 10.07, need not purifying and promptly can be used for next step.

^*Perhaps, also can use by add the 6M HCl of AcCl preparation to anhydrous methanol.

Step 7

Under-78 ℃, with the CH of amine hydrochlorate 10.07 ₂Cl ₂(200ml) solution Et ₃N (45.0mL, 315mmol) and Boc ₂(45.7g 209mmol) handles O.Then reaction mixture is at room temperature stirred and spend the night, (2M, 200mL) dilution is extracted into CH with HCl ₂Cl ₂With the organic layer drying (MgSO that merges ₄), filtering, vacuum concentration by chromatography (EtOAc/Hex 1: 4) purifying, obtains hydroxy ester 10.08.

Step 8.

With methyl esters 10.08 (3g, THF/H 10.5mmol) ₂O (1: 1) solution LiOHH ₂(645mg 15.75mmol) handles O, at room temperature stirs 2h.With reaction mixture the HCl aqueous solution (1M, 15ml) acidifying, vacuum concentration.With residue dried under vacuum, quantitative yield obtains 10.09.

Step 9

CH with acid 10.09 (from more than) ₂Cl ₂(50mL) and DMF (25mL) solution NH ₄Cl (2.94g, 55.5mmol), EDCl (3.15g, 16.5mmol), HOOBt (2.69g, 16.5mmol) and NMM (4.4g 44mmol) handles.Reaction mixture was at room temperature stirred 3 days.The solvent vacuum is removed, residue with the HCl aqueous solution (250mL) dilution, is used CH ₂Cl ₂Extraction.With the saturated NaHCO of organic layer that merges ₃Solution washing, dry (MgSO ₄), filtering, vacuum concentration obtains 10.10, and it is untreated in later step and directly uses.(perhaps, also can be under 0 ℃, by make 10.06 (4.5g, 17.7mmol) and H ₂O ₂The aqueous solution (10mL), LiOHH ₂(820mg is 20.8mmol) at 50mL CH for O ₃React 0.5h among the OH, directly obtain 10.10)

Step 10

10.10 the solution that will obtain in previous step is rapid is dissolved in the two  alkane solution of 4N HCl, at room temperature stirs 2h.With the reaction mixture vacuum concentration, obtain intermediate 10.11, be solid, need not during use to be further purified.

Step 11

Basically use above-mentioned steps 9,10 methods, obtain the intermediate 10.12 that needs with suitable reagent by compound 10.09.

Preparation intermediate 11.01

Step 1

To 4-pentyne-1-alcohol 11.02 (4.15g; Aldrich) add Dess-MartinPeriodinane (30.25g in the solution; Aldrich), the mixture that obtains is stirred 45min, add (uncle-butoxy carbonyl methylene radical) triphenyl phosphorane (26.75g then; Aldrich).The dark reactant stirring that obtains is spent the night, with the EtOAc dilution, with sodium sulfite aqueous solution, saturated NaHCO ₃The aqueous solution, water, salt water washing, drying.The volatile matter decompression is removed, and residue is made elutriant through purification by silica gel column chromatography with the 1%EtOAc/ hexane, obtains the compound 11.03 (3.92g) that needs.Also obtain some impure components, but shelve this moment earlier.

Step 2

N-propyl alcohol (20ml with alkene 11.03 (1.9g); Aldrich)) solution, benzyl carbamate (4.95g; Aldrich) n-propyl alcohol (40ml) solution, NaOH (1.29g) water (79ml) solution, t-butyl hypochlorate (3.7ml), (DHQ) ₂PHAL (0.423g; Aldrich)) n-propyl alcohol (37.5ml) solution and potassium osmate: dehydrate (0.1544g; Aldrich) with in Angew.Chem.Int.Ed.Engl (1998), 35, (23/24), the method of describing in the 2813-7 page or leaf obtains crude product, through purification by silica gel column chromatography, uses EtOAc: hexane (1: 5) wash-out, obtain the amino alcohol 11.04 (1.37g, 37%) of needs, be white solid.

Step 3

The two  alkane (20ml that in ester 11.04 (0.700g), add 4M HCl; Aldrich) solution is at room temperature placed the mixture that obtains and is spent the night.The volatile matter decompression is removed, obtain acid 11.05 (0.621g), be white solid.

Step 4

At room temperature, successively with bop reagent (3.65g; Sigma), triethylamine (3.45ml) adds in methylene dichloride (20ml) solution of carboxylic acid 11.05 (2.00g) and allylamine (0.616ml), the mixture stirring that obtains is spent the night.Reaction mixture is distributed between the EtOAc and the 10%HCl aqueous solution.Organic phase is separated, with saturated sodium bicarbonate aqueous solution, water washing, dry (sal epsom).Crude reaction product is through purification by silica gel column chromatography, with (EtOAc: hexane; 70: 30) make elutriant, obtain the acid amides 11.01 (1.73g) of needs, be viscous yellow oil.

Preparation intermediate 12.03 and 12.04

Step 1

Basically the method for describing with intermediate 10.11 step 3-8 is converted into compound 12.01 material 12.02 that needs.

Step 2

Basically with intermediate 10.11 steps 9,10 methods of describing, compound 12.02 is converted into the intermediate 12.03 that needs.

Step 3

Basically the method for describing with intermediate 10.12 steps 11 is converted into compound 12.02 in the intermediate 12.03 that needs.

Preparation intermediate 13.01

Step 1

Under 0 ℃-5 ℃, stir down, in 2h, (16.5g is 0.16mol) with Glyoxylic acid hydrate H to 1-nitrobutane 13.02 ₂The O aqueous solution (28.1g, 0.305mol) and drip in the solution of MeOH (122ml) triethylamine (93mL, 0.667mol).Make solution be warming up to room temperature, stirring is spent the night, and is concentrated into driedly, obtains oily matter.Then oily matter is dissolved in H ₂O is acidified to pH=1 with 10%HCl, extracts with EtOAc subsequently.With the organic solution salt water washing that merges, through Na ₂SO ₄Drying is filtered, and is concentrated into driedly, obtains product 13.03 (28.1g, 99% yield).

Step 2

Stir down, (240g adds 10%Pd/C (37g) in acetate 1.35mol) (1.25L) solution to compound 13.03.Under 59psi, with the solution hydrogenation 3h that obtains, hydrogenation is spent the night under 60psi then.Then with acetate evaporation,, grind with MeOH and ether then with methylbenzene azeotropic 3 times.Then solution is filtered,, obtain 13.04, be pale solid (131g, 0.891mol, 66%) with methylbenzene azeotropic twice.

Step 3

At 0 ℃, stir down, to amino acid/11 3.04 (2.0g, two  alkane (10ml) and H 13.6mmol) ₂Adding 1N NaOH solution in O (5ml) solution (4.3ml, 14.0mmol).With the solution stirring that obtains 10 minutes, (0.110g 14.0mmol), stirred 15 minutes down at 0 ℃ to add tert-Butyl dicarbonate subsequently.Then solution is warming up to room temperature, stirred 45 minutes, in refrigerator, preserve and spend the night, be concentrated into driedly, obtain thick material.In the EtOAc of this thick material (100ml) solution and ice, add KHSO ₄(3.36g) and H ₂O (32ml) stirred 4-6 minute.Then organic layer is separated, with water layer EtOAc extracting twice, with organic layer water, the salt water washing that merges, through Na ₂SO ₄Drying is filtered, and is concentrated into driedly, obtains product 13.05, is transparent jelly (3.0g, 89% yield).

Step 4

Basically the method for describing with intermediate 10.12 steps 11 is converted into compound 13.05 in the intermediate 13.01 that needs.

Preparation intermediate 14.01

Step 1

Basically the method for describing with intermediate 13.01 step 1-3 is converted into compound 14.02 material 14.03 that needs.

Step 2

Basically the method for describing with intermediate 10.12 steps 11 is converted into compound 14.03 in the intermediate 14.01 that needs.

Preparation intermediate 15.01

Step 1

Under 0 ℃, (9g slowly adds (about 15min) 4-iodo-1,1,1-trifluoro butane 15.02 (10g, ether 42.0mmol) (25mL) solution in ether 58.5mmol) (25mL) suspension to silver nitrite by feed hopper.Under 0 ℃, the mixture vigorous stirring with obtaining is warming up to room temperature.Behind the 50h, solid matter is passed through the Celite pad filtering.Diethyl ether solution vacuum concentration with obtaining obtains 15.03, is colorless oil, need not during use to be further purified.

Step 2

Basically the method for describing with intermediate 13.01 step 1-3 is converted into compound 15.03 material 15.04 that needs.

Step 3

Basically the method for describing with intermediate 10.12 steps 11 is converted into compound 15.04 in the intermediate 15.01 that needs.

Preparation intermediate 16.01

Handle acid 16.02 (Winkler, D. by above-mentioned (preparation intermediate 10.12); Burger, K., Synthesis, 1996,1419), the intermediate 16.01 that obtains expecting.

Preparation P2/P3-P2 part

Preparation intermediate 20.01

Press R.Zhang and J.S.Madalengoitia (J.Org.Chem.1999,64,330) method, preparation amino ester 20.01, difference are to make the amino acid of Boc-protection and the methanol solution of HCl to react, and the Boc group is dissociated.

(noting: in the synthetic variation of report, replace the sulfonium ylide) with corresponding  ylide.

Preparation intermediate 20.04

Step 1

Under 0 ℃, (Senn chemicals, 664g is 24.1mmol) with amine hydrochlorate 20.01 (4.5g, CH 22mmol) with commercially available amino acid Boc-Chg-OH 20.02 ₂Cl ₂(100mL) solution is handled with bop reagent, at room temperature stirs 15h.With the reaction mixture vacuum concentration, with the dilution of the 1M HCl aqueous solution, be extracted into EtOAc (3 * 200mL) then.With the saturated NaHCO of organic layer that merges ₃(200mL) washing, dry (MgSO ₄), filter vacuum concentration, chromatography (SiO ₂, EtOAc/Hex 3: 7), obtain 20.03 (6.0g), outer colorless solid.

Step 2

With methyl esters 20.03 (4.0g, THF/H 9.79mmol) ₂O (1: 1) solution LiOHH ₂(401mg 9.79mmol) handles O, at room temperature stirs 3h.With the reaction mixture acidifying, vacuum concentration obtains the intermediate free acid 20.04 that needs with the HCl aqueous solution.

Preparation intermediate 20.07

Step 1

Anhydrous CH with Boc-tert-Leu 20.05 (Fluka, 5.0g 21.6mmol) ₂Cl ₂/ DMF (50mL, 1: 1) solution is cooled to 0 ℃, with amine salt 20.01 (5.3g, 25.7mmol), NMM (6.5g, 64.8mmol) and bop reagent (11.6g, 25.7mmol) processing.Reactant is at room temperature stirred 24h,, use CH with the HCl aqueous solution (1M) dilution ₂Cl ₂Extraction.With the organic layer that merges with HCl (aqueous solution, 1M), saturated NaHCO ₃, the salt water washing, dry (MgSO ₄), filtering, vacuum concentration is through chromatography (SiO ₂, acetone/hexane 1: 5) and purifying, obtain 20.06, be colorless solid.

Step 2

(4.0g, 10.46mmol) solution is dissolved in the two  alkane solution of 4M HCl, at room temperature stirs 3h with methyl esters 20.06.With the reaction mixture vacuum concentration, obtain amine hydrochlorate 20.07, need not purifying during use.

Preparation intermediate 21.01

Step 1

At room temperature, stir down, to N-Boc-3,4-dehydroproline 21.02 (5.0g, 23.5mmol), tert-Butyl dicarbonate (7.5g, 34.4mmol) and 4-N, the N-Dimethylamino pyridine (0.40g, add in acetonitrile 3.33mmol) (100mL) solution triethylamine (5.0mL, 35.6mmol).Under this temperature, with the solution stirring 18h that obtains, then with its vacuum concentration.The dark-brown residue with 10-25%EtOAc/ hexane wash-out, obtains product 21.03 through dodging the formula column chromatography purification, is light yellow oil (5.29g, 84%).

Step 2

At room temperature, stir down, to dehydroproline derivative 21.03 (10.1g, 37.4mmol), (1.60g adds 50% aqueous sodium hydroxide solution (120g) to benzyltriethylammoinium chloride in chloroform 7.02mmol) (120mL) solution.Behind vigorous stirring 24h under this temperature, use CH ₂Cl ₂(200mL) and ether (600mL) dark mixture is diluted.After the liquid layer separation, with aqueous solution CH ₂Cl ₂/ Et ₂O (1: 2,3 * 600mL) extractions.With organic solution drying (MgSO ₄), concentrate.Residue with 5-20%EtOAc/ hexane wash-out, obtains 9.34g (71%) 21.04 through dodging the formula column chromatography purification, is pale solid.

Step 3

At room temperature, with 21.04 (9.34g, CH 26.5mmol) ₂Cl ₂(25ml) and CF ₃CO ₂H (50mL) solution stirring 4.5h then with its vacuum concentration, obtains 21.05 brown residue, and it need not to be further purified when step 4 is used.

Step 4

Concentrated hydrochloric acid (4.5ml) is added in methyl alcohol (70ml) solution of step 3 residue 21.05, the mixture that obtains is warming up to 65 ℃ in oil bath.Behind the 18h,, obtain brown oil 21.01, need not during use to be further purified the mixture vacuum concentration.

Preparation intermediate 22.01

Step 1

Stir down, with two (trimethyl silyl) amination potassium (toluene solution of 158ml 0.5M; 79mmol) add brominated propyl group triphenyl  (33.12g; 86.4mmol) anhydrous tetrahydro furan (130ml) suspension in, at room temperature, under nitrogen atmosphere, the orange mixture that obtains is stirred 1h, add aldehyde 22.02 (9.68g then; 42.2mmol) THF (8ml) solution.Under nitrogen atmosphere, make reactant backflow 2h then.After the cooling, add methyl alcohol, ether and Rochelles salt.Organic phase is separated, use the salt water washing, drying, concentrating under reduced pressure.Crude reaction product with EtOAc-hexane (1: 99)-EtOAc-hexane (5: 95) wash-out, obtains alkene 22.03 (8.47g) through purification by silica gel column chromatography, is yellow oil.

Step 2

At room temperature, by the 14.2ml Acetyl Chloride 98Min. is added drop-wise in the cold methanol, with the solution dilution that obtains to 200ml, the MeOH/MeOAc solution of preparation 1M HCl.

With carbamate 22.03 (9.49g; 37.5mmol) be dissolved in methyl alcohol (12ml), it is added in the MeOH/MeOAc solution (150ml) of 1M HCl, in ice bath, cool off simultaneously.Under this temperature, the mixture that obtains is kept 1h, it is abundant to remove ice then, at room temperature continues to stir and spends the night.The volatile matter decompression is removed, obtain yellow oil, next step need not purifying when using.

Yellow oil is dissolved in the mixture of THF (30ml) and MeOH (20ml), with triethylamine (15ml; 108mmol) handle until pH value of solution=9-10.After inserting ice bath, with mixture N-Boc-Gly-OSu (11.22g; 41mmol) handle.Remove ice bath, reactant is at room temperature stirred 1h.The volatile matter decompression is removed, and residue with methyl alcohol (1-3%)/methylene dichloride wash-out, obtains the acid amides 22.04 (9.09g) that needs through purification by silica gel column chromatography.

Step 3

With alcohol 22.04 (9.09g; 33.6mmol) be dissolved in acetone (118.5ml), with 2,2-Propanal dimethyl acetal (37.4ml; 304mmol) and BF ₃: Et ₂O (0.32ml; 2.6mmol) handle, the mixture that obtains is at room temperature stirred 5.5h.Reaction soln is handled with several triethylamines, the volatile matter decompression is removed.Residue with 5-25%EtOAc/ hexane wash-out, obtains N, O-acetal 22.05 (8.85g) through purification by silica gel column chromatography.

Step 4

Under nitrogen atmosphere, with carbamate 22.05 (8.81g; 28.4mmol) be dissolved in acetonitrile (45ml), solution is cooled to-40 ℃.Add pyridine (6.9ml successively; 85.3mmol), nitronium tetrafluoroborate  (nitrosium) (6.63g; 56.8mmol), the reaction mixture that obtains is remained on below 0 ℃, show that until TLC there be (about 2.25h) in no raw material.Add tetramethyleneimine (20ml; 240mmol), it is abundant to remove cooling, at room temperature continue to stir 1h, then the volatile matter decompression is removed.Make residue fast by silicagel pad, obtain yellow oil.

Yellow oil is dissolved in dry-out benzene (220ml), adds acid chloride (0.317g; 1.41mmol), then under nitrogen atmosphere, with the mixture heating up backflow 1.5h that obtains.After the cooling, the volatile matter decompression is removed, dark residue with EtOAc-hexane (1: 4) wash-out, obtains i through purification by silica gel column chromatography) trans-pyrrolidone 22.06 (1.94g), obtain ii) cis-pyrrolidone 22.07 (1.97g) subsequently.

Step 5

MeOAc/MeOH solution (10ml with freshly prepd 1M HCl; With above-mentioned) add N, in the O-acetal 22.06, at room temperature stir 1h.The solvent decompression is removed, and residue is made elutriant through purification by silica gel column chromatography with the 0-4%MeOH/ methylene dichloride, obtains the alcohol 22.08 (1.42g) of needs, is yellow oil.

Step 6

To lactan 22.08 (1.29g; 8.44mmol) anhydrous tetrahydro furan (55ml) solution in add lithium aluminum hydride (2.40g; 63.2mmol), with the mixture backflow 8h that obtains.After the cooling, add entry, the 15%NaOH aqueous solution successively, make the mixture that obtains by diatomite filtration, solid THF and MeOH thorough washing, the solvent decompression is removed, residue is dissolved in methylene dichloride, drying again, concentrating under reduced pressure obtains tetramethyleneimine, need not purifying during use.

Under-60 ℃, under nitrogen atmosphere, with Hunigs alkali (4.5ml; 25.8mmol) adding N-Boc-L-tert-Leu-OH (1.76g; 7.6mmol), described thick tetramethyleneimine and HATU (2.89g; 7.6mmol) in the mixture in anhydrous methylene chloride (50ml).Allow the reactant that obtains slowly reach room temperature, spend the night.Add EtOAc, with yellow solution with rare HCl aqueous solution, saturated sodium bicarbonate aqueous solution, water, salt water washing.With organic layer drying, concentrating under reduced pressure.Residue is used EtOAc through purification by silica gel column chromatography: hexane (1: 3) wash-out obtains the acid amides 22.09 (2.00g) that needs.

Step 7

With alcohol 22.09 (2.00g; 5.67mmol) be dissolved in acetone (116ml), in ice bath, cool off 10min.Then this solution is added cold Jones reagent (14.2ml; About 2mmol/ml) in, the mixture that obtains is stirred 0.5h down at 5 ℃, remove cooling bath.With reactant restir 2h at room temperature, add then in EtOAc (100ml) solution of sodium sulfate (28.54g), diatomite (15g).Behind the 1min, add Virahol (15ml), and then stir 10min, filter.Filtrate decompression is concentrated, obtain brown oil, it is dissolved in EtOAc.With this solution with water, 3% aqueous citric acid solution, salt water washing, drying concentrates, and obtains the carboxylic acid 22.01 (1.64g) of needs, is white solid.

Preparation intermediate 23.01

Step 1

Add in the mixture in anhydrous methylene chloride (35ml) to ester 23.02 (6.0g) and molecular sieve (5.2g) tetramethyleneimine (5.7ml, 66.36mmoL).At N ₂Down, at room temperature, the brown soup compound that obtains is stirred 24h, filter, use anhydrous CH ₃The CN washing.The filtrate that merges is concentrated, obtain the product 23.03 that needs.

Step 2

Go on foot the CH of product 23.03 forward ₃Add anhydrous K in CN (35ml) solution ₂CO ₃, methylallyl chloride (2.77g, 30.5mmoL), NaI (1.07g, 6.7mmoL).At N ₂The soup compound that obtains is stirred 24h at ambient temperature down.Add 50ml ice-cold water, 2NKHSO successively ₄Solution is until pH 1.Add EtOAc (100ml), mixture is stirred 0.75h.Collect the merging organic layer, use the salt water washing, through MgSO ₄Drying, evaporation obtains the product 23.04 that needs.

Step 3

(2.7g 8.16mmoL) is dissolved in two  alkane (20ml), handles with freshly prepd 1N LiOH (9mL) with preceding step product 23.04.At N ₂Reaction mixture is stirred 20h at ambient temperature down.Reaction mixture is dissolved in EtOAc, uses H ₂The O washing.The water that merges is cooled to 0 ℃, is acidified to pH 1.65 with 1N HCl.(2 * 100mL) extract with EtOAc with turbid mixture.With the organic layer salt water washing that merges, through MgSO ₄Drying concentrates, and obtains the acid 23.05 (3.40g) that needs.

Step 4

To NaBH (OAc) ₃(3.93g, CH 18.5mmoL) ₂Cl ₂(55mL) add the preceding anhydrous CH that goes on foot product 23.05 in the suspension ₂Cl ₂(20mL) solution and acetate (2mL).Soup compound is stirred 20h at ambient temperature.Ice cold water (100mL) is added soup compound, stir 1/2h.Organic layer is separated, filter, drying, evaporation obtains the product 23.06 that needs.

Step 5

Go on foot forward and add excessive CH in MeOH (40mL) solution of product 23.06 (1.9g) ₂N ₂/ Et ₂The O solution-treated, stirring is spent the night.Reaction mixture is concentrated into dried, obtains thick residue.Residue is through silica gel column chromatography, with EtOAc/ hexane gradient wash-out, obtain 1.07g pure need product 23.07.

Step 6

Go on foot the anhydrous CH of product 23.07 (1.36g) forward ₂Cl ₂(40mL) add BF in the solution ₃Me ₂O (0.7mL) handles.Reaction mixture is stirred 20h at ambient temperature, use saturated NaHCO ₃1/2h is stirred in (30ml) quencher.Organic layer is separated, with the organic layer salt water washing that merges, through MgSO ₄Drying concentrates, and obtains thick residue.Make residue chromatography on silica gel,, obtain the compound 23.08 that 0.88g needs with EtOAc/ hexane gradient wash-out.

Step 7

At room temperature, go on foot forward in MeOH (30mL) solution of product 23.08 (0.92g) and add 10%Pd/C (0.16g), at ambient temperature, hydrogenation under 1 normal atmosphere.Reaction mixture is stirred 4h, be concentrated into driedly, obtain the compound 23.01 that needs.

Preparation P3 part

Preparation intermediate 50.01

Step 1

In the MeOH of 50.02 (15g) (150mL) solution, add dense HCl (3-4mL), make mixture backflow 16h.Reaction mixture is cooled to room temperature, concentrates.Residue is dissolved in ether (250mL), with cold saturated sodium bicarbonate solution and salt water washing.With organic layer drying (Na ₂SO ₄), concentrate, obtain methyl esters 50.03 (12.98g), it need not to be further purified and can carry out the next step.

Step 2

Under nitrogen atmosphere, above methyl esters 50.03 is dissolved in methylene dichloride (100ml), be cooled to-78 ℃.In 2h, and dropping DIBAL (dichloromethane solution of 1.0M, 200ml).In 16h, make reaction mixture be warming up to room temperature.Reaction mixture is cooled to 0 ℃, is added dropwise to MeOH (5-8mL).Stir down, slowly add 10% soluble tartrate sodium water solution (200mL).With methylene dichloride (100mL) dilution, separate organic layer (some white precipitates are arranged).Organic layer is washed dry (Na with 1N HCl (250mL), salt solution (200mL) ₂SO ₄), concentrate, obtain alcohol 50.04 (11.00g), be transparent oily matter.

Step 3

Under nitrogen atmosphere, be dissolved in methylene dichloride (400mL) with above pure 50.04, be cooled to 0 ℃.Add PCC (22.2g) in batches, in 16h, reaction mixture slowly is warming up to room temperature.Reaction mixture with ether (500mL) dilution, is filtered by Celite pad.Filtrate is concentrated, residue is dissolved in ether (500mL).Make it pass through silicagel pad, filtrate is concentrated, obtain aldehyde 50.05, it need not to be further purified and can carry out the next step.

Step 4

Mainly with Chakraborty etc. (Tetrahedron, 1995,51 (33), method 9179-90) is converted into above aldehyde 50.05 material 50.01 that needs.

Preparation embodiment 100:

The preparation of table 1 formula 100 compounds

The amine of part I: preparation formula 100-1

Step 1:

(OmegaChem, Canada) (15g is added dropwise to methylsulfonyl chloride (5.3mL, 68mmol, 1.1 equivalents) to commercially available N-t-BOC-L-cyclohexyl glycinol 100-2 under 0 ℃ in DCM 62mmol) (170mL) and pyridine (17mL) solution.After the adding, reactant is warming up to room temperature, and stirred 18 hours.Reactant dilutes with EtOAc, and with 120mL ice-cold water washing 2 times, uses salt solution (100mL) washing then.Organic layer is through MgSO ₄Drying is filtered, and concentrates, and obtains the thick oily matter 100-3 of 20.9g.

Step 2:

In the DMF (7mL) of 100-3 (3.4g crude product) solution at room temperature, add NaN3 (9.62g), reactant is warming up to 65 ℃.After 5 hours, with the reactant cooling, with EtOAc (100mL) and ice-cold water (100mL) dilution.After the extraction, organic layer water and salt water washing are through MgSO ₄Drying is filtered, and concentrates, and obtains thickness oily matter.This resistates through HPFC, is used 40+M post and 2%-8%EtOAC/ hexane purifying.Purifying obtains 1.06g trinitride 100-4.

Step 3:

Under nitrogen atmosphere, in the MeOH of trinitride 100-4 (1.06g) (35mL) solution at room temperature, add 100mg Pd/C (10%).Under the room temperature,, and stirred 18 hours, filter by Celite pad then, concentrate, obtain 100-1, be thickness oily matter (0.85g) the reactant hydrogen purge.

The amine of part II: preparation formula 100-5

Step 1:

Commercially available (Sigma-Aldrich) 3 under 0 ℃, 4-diethoxy-3-cyclobutene-1, (15mmol is added dropwise to 10mmol Me in EtOH 2.5g) (50mL) solution to 2-diketone 100-6 ₂NH (5mL, 2.0M THF solution).Reactant is warming up to room temperature gradually.After 2 hours, reactant is concentrated,, use 25+M post and 20%-60%EtOAC/ hexane purifying through HPFC.Purifying obtains 1.95g product 100-7.

Step 2:

To amine 100-1 (250mg, add in EtOH 1.48mmol) (5mL) solution at room temperature cyclobutenedione 100-7 (1.2 equivalents, 190mg) and DIPEA (0.1mL).At room temperature reactant was stirred 1 hour, reflux then and spend the night.After 18 hours, form white precipitate.Reaction is stopped and cooling off.White precipitate is leached, ethyl acetate rinse, dry under the nitrogen gas stream, obtain the required product 100-8 of 445mg.

Step 3:

(228mg adds Cs in DMF 0.67mmol) (10mL) solution to amine 100-8 under 0 ℃ successively ₂CO ₃(1.5 equivalents, 1mmol, 325mg) and MeI (1.8 equivalents, 1.2mmol, 0.075mL).At room temperature reactant is stirred and spend the night, then with ethyl acetate and water dilution.Water layer is used ethyl acetate extraction again.With the organic layer salt water washing that merges, through MgSO ₄Drying is filtered and is concentrated.Through HPFC, use 80%EtOAC/ hexane purifying.Obtain the required 100-9 of 200mg.

Step 4:

The two  alkane solution that in 30mg amine 100-9 (0.1mmol), add 3mL 4.0N HCl.At room temperature reactant is stirred, until detecting less than raw material.Behind the 1h,, obtain amine salt 100-5, be light yellow solid the reactant vacuum concentration.

The isocyanic ester of part III: preparation formula 100-10

Step 1:

To amine 100-11 (10g, 72mmol) add HATU (1.05 equivalents in DCM (200mL)-20 ℃ solution of (according to R.Zhang and the preparation of J.S.Madalengoitia (J.Org Chem.1999,64,330) method), 28.8g), Boc-L-Terleu 100-12 (AldrichChemical Co., Milwaukee, Wisconsin, USA, 1.1 equivalent, 79.2mmol, 18.3g) and DIPEA (0.2mol, 40mL).Reactant is stirred 24h, with the ethyl acetate dilution, wash then with sodium bicarbonate.Organic layer is used citric acid and salt water washing successively.Organic layer is through MgSO ₄Drying is filtered and vacuum concentration.At 0 ℃, residue 100-13 (72mmol) is dissolved in acetone (1.2L).Then, add 5 equivalent J ones reagent (138mL, 360mmol by the 91g chromium trioxide is dissolved in the 70mL vitriol oil, and are diluted to the 300mL preparation).Behind the 45min, TLC detects less than raw material.Add Virahol (40mL) and 500mL ethyl acetate.

This green solution is filtered by Celite pad, and filtrate is concentrated into dried.Residue dilutes with 10% yellow soda ash, uses extracted with diethyl ether.Water layer is acidified to Ph=2 with 3.0N HCl then, and the usefulness ethyl acetate extraction (3 times, 200mL).With organic layer through MgSO ₄Drying is filtered and vacuum concentration.Obtain 21.55g intermediate 100-14.

Step 2:

(10.4g adds HATU (1.05 equivalents, 29.4mmol in DCM 28mmol) (300mL)-20 ℃ solution to 100-14,11.2g), amine salt 12.03 (1.0 equivalents, 28mmol, 5.48g, according to the preparation intermediate, prepare the method preparation that P1-P ' part is described).Behind-20 ℃ of 10min, and adding DIPEA (3.6 equivalents, 100mmol, 17.4mL).Reactant is stirred 16h under this temperature.After 16, reactant dilutes with ethyl acetate, uses sodium bicarbonate, citric acid (10%w/w) and salt water washing successively.Organic layer is through MgSO ₄Drying is filtered and vacuum concentration, obtains 14g intermediate 100-15.

Step 3:

At room temperature, with Et ₃((4 equivalents, 6.92mmol is 1.33g) in the mixture of ethyl acetate (12mL) 0.72mL) to join 100-15 crude product (1.06g, 1.73mmol theoretical amount) and EDCl for 3 equivalents, 5.2mmol for N.After the adding, DMSO (4.5mL) is slowly added.(0.4mL), and temperature remains between 20 to 30 ℃ for 3.6 equivalents, 6.22mmol to add methylsulfonic acid subsequently.Reactant is stirred 1h.

Behind the 1h, TLC show the reaction finish.At 0 ℃, add the cold mixt of ethyl acetate (12mL) and ice cold water (2mL).After 2 minutes, two-phase mixture is left standstill layering.Upper strata organic layer water and salt water washing.Organic layer is through MgSO ₄Drying is filtered and vacuum concentration.With residue through HPFC, 25+M, 15%-60% (ethyl acetate)/hexane purifying.Purifying obtains (0.6g) ketone group acid amides.The two  alkane solution that in ketone group acid amides (0.6g) solution at room temperature, add 25mL 4.0N HCl.Reactant at stirring at room 1h, is observed reaction and finished, be concentrated into about 5mL then, with heptane and ether (each 10mL) dilution.The gained white precipitate is filtered, dry under nitrogen gas stream, obtain the hydrochloride of 0.49g (81% yield) amine.To amine salt (50mg, add in 0 ℃ of solution of methylene dichloride 0.1mmol) (7mL) saturated sodium bicarbonate aqueous solution (7mL) photoreactive gas (0.053mL, 1.1 equivalents, 0.11mmol).Continue immediately to stir again, with ice-cooled reaction mixture high-speed stirring 30min.Then, organic phase (lower floor) is separated, through MgSO ₄Drying uses the cooling bath vacuum concentration to half volume.Then,, be diluted to 15mL, fresh use (part IV) in the next step with methylene dichloride with isocyanic ester 100-10 impouring graduated cylinder.

Part IV: preparation table 1 Chinese style 100 compounds

According to universal method C: to amine 100-5 (33mg, 0.1mmol) add in 0 ℃ of solution of methylene dichloride (5mL) isocyanic ester 100-10 (1 equivalent, 0.1mmol), add then DIPEA (0.4mmol, 0.07mL).Reactant at stirring at room 2h, with the ethyl acetate dilution, is used saturated ammonium chloride and salt water washing then.Organic layer is through MgSO ₄Drying filters and is concentrated into dried.Residue with 5%MeOH/ ethyl acetate purifying, obtains 9mg formula 100 products (10% yield) through plate; LCMS:(712.2:M+1).

The HCV inhibitor 110,113 and 133 that table 1 is described uses formula 100-5 intermediate preparation according to aforementioned universal method.

Preparation embodiment 106

Preparation table 1 Chinese style 106 compounds

Part I: preparation formula 106-1 amine

According to preparation embodiment 100 described methods, in step 1, substitute commercially available N-t-BOC-L-cyclohexyl glycinol 100-2, preparation amine 106-1 with corresponding commercially available N-t-BOC-L-tertiary butyl glycinol.

The amine salt of part II: preparation formula 106-2.

According to the described method of preparation embodiment 100 part II, in step 2, substitute formula 100-1 amine, preparation amine 106-2 with aforementioned formula 106-1 amine.

Part III: preparation formula 106 compounds

According to the described method of preparation embodiment 100 part IV, substitute amine 100-5, preparation formula 106 compounds with amine salt 106-2.

The HCV inhibitor 115,121,135,147 and 148 that table 1 is described uses formula 106-1 intermediate preparation according to aforementioned universal method.

Preparation embodiment 104

Preparation table 1 Chinese style 104 compounds

Part I: preparation formula 104-3 amine

Step 1:

Under-78 ℃, in 30 seconds, to commercially available squaric acid diethyl ester 104-1 (AldrichChemical Co., Milwaukee, Wisconsin, USA, 1g, add in THF 5.88mmol) (20mL) solution t-BuLi (5.93mmol, 3.5mL).

Behind the 50min, 0.5 equivalent t-BuLi is added in the reactant, under-40 ℃, continue to stir 60min.Then, under-40 ℃, be added dropwise to TFAA (1mL, 7.06mmol).Behind the 10min, add 10% ammonium chloride (aqueous solution) (10mL).Gained solution is warming up to room temperature, and impouring ether (50mL)/5% sodium bicarbonate (aqueous solution) is (80mL) in the mixture.With the water layer extracted with diethyl ether.The organic layer salt water washing that merges is then through MgSO ₄Dry.Be concentrated into do after, residue is through HPFC, the 25+M column purification is an elutriant with 5～20% ethyl acetate/hexane, obtains 0.874g product 104-2.

Step 2:

The method of preparation formula 104-3 intermediate is similar with the amine 100-1 preparation method of preparation embodiment 100, replaces formula 100.7 compounds with formula 104-2 compound in the step 2.In addition, the amine hydrochlorate preparation method of formula 104-3 is similar to the preparation method of amine 100-9 in preparation embodiment 100 steps 4.

Part II: preparation formula 104-4 intermediate

To solution at room temperature (10g)

In formula 20.03 intermediates (5.4g) (by the preparation of preparation formula 20.04 intermediate steps 1) solution at room temperature, add 50mL 4.0N HCl/ two  alkane solution.Reactant is at room temperature stirred 18h, be concentrated into about 20mL then, with heptane and ether dilution (each 100mL).Gained white soup compound is leached, obtain required amine hydrochlorate, be white powder (3.32g).With amine salt (3g) be added to saturated sodium bicarbonate aqueous solution (50mL), (2 equivalents, 16.8mmol is in 0 ℃ of solution 8.9mL) for DCM (50mL) photoreactive gas.Stir rapidly immediately, with ice-cooled reaction mixture high-speed stirring 1 hour.After 1 hour, organic phase (lower floor) is separated, then, through anhydrous MgSO ₄Drying, vacuum concentration is to about 20mL.Isocyanic ester is diluted to 34mL (DCM), uses with 0.25M solution.

Part III: preparation formula 104-6 intermediate

Step 1:

(1.15g adds 1.1 equivalent isocyanic ester 104-4 (17.6mL) in 0 ℃ of solution of DCM 4mmol) (20mL), add DIPEA (4 equivalents, 16mmol 2.8mL) then to amine salt 104-3.Reactant is warming up to room temperature, stirs 1h, with the ethyl acetate dilution, use 10N HCl (50mL) and salt water washing successively then.Organic layer is through MgSO ₄Drying is filtered and is concentrated.Residue is through HPFC, 25+M, and 15-60% ethyl acetate/hexane purifying obtains formula 104-5 intermediate (2.31g, 3.85mmol, 96% yield).

Step 2:

(2.31mg adds CsCO in 0 ℃ of solution of DMF 3.85mmol) (50mL) successively to formula 104-5 intermediate ₃(1.5 equivalents, 5.8mmol, 1.9g) and MeI (1.8 equivalents, 7mmol, 0.5mL).Reactant is at room temperature stirred 2h, and this moment, MS showed that no raw material exists in the desired substance.Reactant is diluted with ethyl acetate and water.Water layer is used ethyl acetate extraction again.The organic layer salt water washing that merges is through MgSO ₄Drying is filtered and is concentrated.Through HPFC40+M, 15%-60% ethyl acetate purifying obtains 2.32g (98%) N-methyl intermediate.To this N-methyl intermediate (2.3g, add in 0 ℃ of solution of two  alkane (30mL) 3.7mmol) 3 equivalent LiOH (1.0N solution, 11.1mL).Behind the 2h, TLC shows that no raw material exists.Reactant adds 10mL 1.0N HCl with ether (100mL) dilution.Organic layer salt water washing is through MgSO ₄Drying and filtration.Concentrated filtrate obtains formula 104-6 intermediate, is light yellow solid (2g, 90% yield).

Part IV: preparation formula 104-7 intermediate

(0.02mmol adds HATU (1.1 equivalents, 0.023mmol in DCM 0.013g) (3mL)-20 ℃ solution successively to acid 104.6,9mg), amine 13.01 is (from preparation intermediate 13.01 steps 4,1.0 equivalent, 0.02mmol, 5mg) and DIPEA (0.02mL).

Under-20 ℃, reactant is stirred 18h, use ethyl acetate (10mL) dilution then, use 1.0N HCl (5mL) and salt water washing successively.With organic layer through MgSO ₄Drying is filtered and is concentrated.Residue with 100% ethyl acetate purifying, obtains 10mg oxyamide 104.7 (65% yield) through the preparation plate.

Part of V: preparation formula 104 compounds

To 104.7 (10mg, adding Dess-Martin reagent (30mg) in DCM 0.13mmol) (3mL) solution at room temperature.Behind the 1h, no raw material exists in the MS analysis revealed desired substance.Reactant dilutes with ethyl acetate, with saturated sodium bicarbonate aqueous solution and Na ₂S ₂O ₃1/1 (5mL) mixture at room temperature stirs 5min together.To respectively be separated, organic layer is through MgSO ₄Drying is filtered and is concentrated.Residue uses 90% ethyl acetate/hexane to be developping agent through preparation plate purifying.Purifying obtains 4mg formula 104 compounds.

Preparation embodiment 112

Preparation table 1 Chinese style 112 compounds

According to preparation embodiment 106 preparation formulas 112 compounds, but substitute formula 106-2 amine with formula 104.3 amine at part III.In addition, the HCV inhibitor 103,107,109,111,114,117,119,123,128,137,140 and 145 that table 2 is described uses formula 104-3 intermediate preparation according to aforementioned universal method.In addition, according to the preparation embodiment 104 the identical method of formula 104-amine, replace t-BuLi with other reagent as (but being not limited to) cyclopropyl (clopropyl)-magnesium chloride, sec.-propyl-magnesium chloride, MeLi, ethyl-magnesium chloride in step 1, difference preparation formula 101-1,116-1,129-1 and 132-1 intermediate, thereby the amine of preparation formula 101-1,116-1,129-1 and 132-1.

The HCV inhibitor 101,105,116,118,120,122,124,125,129,130,131,132,134,136,143,144 and 146 that table 2 is described uses formula 101-1,116-1,129-1 and 132-1 intermediate preparation according to aforementioned universal method.Ki ^*Scope shows below: scope A:Ki ^*≤ 75nM; Scope B:Ki ^*＞75nM.

The present invention relates to new HCV proteinase inhibitor.The ability of available their inhibition HCV NS2/NS4a serine proteases proves this effectiveness.The universal method of this proof is described by following external test.

Measure the HCV protease inhibiting activity:

Spectrophotometry: can pass through following R.Zhang etc., Analytical Biochemistry, the method that 270 (1999) 268-275 describe is carried out HCV serine protease spectrophotometry to The compounds of this invention, and document disclosure is attached to herein by reference.Mensuration based on the ester substrate protein hydrolysis that adds lustre to is applicable to continuous monitoring HCV NS3 protease activity.Substrate is derived from NS5A-NS5B catenation sequence (Ac-DTEDVVX (Nva), wherein X=A or P) the P side chain, its C-terminal carboxyl(group) is by one of 4 different color development alcohol (3-or 4-nitrophenols, 7-hydroxy-4-methyl-tonka bean camphor or 4-phenylazo phenol) esterification.Illustrate below that ester substrate synthetic, that characterize and use these new spectrophotometrys carries out high flux screening and to the detailed kinetics evaluation of HCV NS3 proteinase inhibitor.

Material and method:

Material: the chemical reagent that is used to measure relevant damping fluid derive from Sigma ChemicalCompany (St.Louis, Missouri).The peptide synthetic agent comes from Aldrich Chemicals, Novabiochem (San Diego, California), Applied Biosystems (Foster City, California) and Perseptive Biosystems (Framingham, Massachusetts).Manually or at the automatic ABI synthesizer of 431A type (from Applied Biosystems) go up synthetic peptide.LAMBDA 12 type UV/VIS spectrophotometers come from Perkin Elmer, and (Norwalk, Connecticut), 96 hole UV plates derive from Corning (Corning, New York).The preheating section can from USA Scientific (Ocala Florida) obtains, 96 orifice plate vortex agitators come from Labline Instruments (Melrose Park, Illinois).The band monochromator Spectramax Plus microtitration card reader derive from Molecular Devices (Sunnyvale, California).

The enzyme preparation: by method (D.L.Sali etc., Biochemistry, 37 (1998) 3392-3401) with previous announcement, the HCV NS3/NS4A proteolytic enzyme (1a system) of preparation reorganization heterodimer.With by the quantitative in advance recombinant HCV proteolytic enzyme of amino acid analysis standard, measure protein concentration by the Biorad staining.Before measuring beginning, with Biorad Bio-Spin P-6 prepacked column, make enzyme store buffer liquid (50mM sodium phosphate pH 8.0,300mM NaCl, 10% glycerine, 0.05% Lauryl.beta.-maltoside and 10mM DTT) and measure damping fluid (25mM MOPSpH 6.5,300mM NaCl, 10% glycerine, 0.05% Lauryl.beta.-maltoside, 5 μ MEDTA and 5 μ M DTT) exchange.

Synthetic and the purifying of substrate: press the synthetic substrates of (the same) report method such as R.Zhang, by using standard scheme (K.Barlos etc., Int.J.Pept.Protein Res., 37 (1991), 513-520) Fmoc-Nva-OH is anchored on the 2-chlorine trityl chloride resin and cause.Use the Fmoc chemistry subsequently, artificial or on the automatic ABI peptide synthesizer of 431 types secretory piece.With methylene dichloride (DCM) solution of 10% acetate (HOAc) and 10% trifluoroethanol (TFE), with the peptide fragment of N-acetylize and full guard and the resin 30min that dissociates, or with the DCM solution of 2% trifluoroacetic acid (TFA) 10min that dissociates.The filtrate and the DCM washings azeotropic vaporization that merge (or are used Na ₂CO ₃The aqueous solution extracts repeatedly), remove and be used for dissociated acid.DCM is through Na ₂SO ₄Drying, evaporation.

With standard acid-pure coupling method (K.Holmber etc., Acta Chem.Scand., B33 (1979) 410-412) assembling ester substrate.Peptide fragment is dissolved in anhydrous pyridine (30-60mg/ml), to wherein adding 10 molar equivalent chromophoric grouies and catalytic amount (0.1 equivalent) tosic acid (pTSA).Add dicyclohexylcarbodiimide (DCC, 3 equivalents), cause linked reaction.Form by HPLC monitoring product, at room temperature, can find after 12-72 hour to react and finish.With pyridine solvent vacuum-evaporation, by further removing with the methylbenzene azeotropic evaporation.DCM solution with 95%TFA makes peptide ester deprotection 2 hours, with anhydrous diethyl ether extraction three times, removes excessive chromophoric group.The substrate that makes deprotection is by reversed-phase HPLC, and purifying on C3 or C8 post is with 30%-60% acetonitrile gradient (using 6 column volumes) wash-out.Total recovery behind the HPLC purifying can be about 20-30%.Molecular weight can pass through the electro-spray ionization mass spectrum confirmation.Under drying conditions, substrate stores with dry powder form.

Substrate and product collection of illustrative plates: in pH 6.5 mensuration damping fluids, obtain substrate and corresponding chromophoric group product collection of illustrative plates.In the 1-cm cuvette (for 3-Np and HMC is 340nm, for PAP be 370nm and be 400nm for 4-Np), with repeatedly dilution, be determined at the optical extinction coefficient at wavelength place, best non-peak.Best non-peak wavelength is defined as: optical density produces wavelength (product OD-substrate the OD)/substrate OD of largest score difference between substrate and product).

Protease assay: under 30 ℃, in 96 hole microtiter plates, carry out the HCV protease assay with 200 μ l reaction mixtures.The mensuration buffer conditions (25mM MOPS pH 6.5,300mM NaCl, 10% glycerine, 0.05% Lauryl.beta.-maltoside, 5 μ M EDTA and 5 μ M DTT) that is used for the NS3/NS4A heterodimer is optimized (D.L.Sali etc., the same)).Usually, the mixture of 150 μ l damping fluids, substrate and inhibitor is inserted in the hole (the DMSO final concentration≤4%v/v), under 30 ℃, about 3 minutes of preincubation.Use the mensuration buffer soln initiation reaction (final volume 200 μ l) of 50 μ l preheating proteolytic enzyme (12nM, 30 ℃) then.Between test period (60 minutes), (for 3-Np and HMC is 340nm at suitable wavelength place, for PAP be 370nm and be 400nm for 4-Np), change (card reader of available use cut-off filter obtains acceptable result) with optical density in the SpectromaxPlus microtitration card reader monitoring panel that is equipped with monochromator.At suitable wavelength place, the proteolysis of ester bond dissociates between monitoring Nva and the chromophoric group, does the nonenzymic hydrolysis contrast with the blank that does not contain enzyme.In 30 times of concentration of substrate scopes (～6-200 μ M), estimate the substrate kinetics parameter.Measure original speed with linear regression, by with data substitution Michaelis-Menten equation, (Mac Curve Fit 1.1 K.Raner) obtains kinetic constant with nonlinear regression analysis.Suppose that enzyme all has activity, calculate turnover number (kcat).

Inhibitor and inactivator evaluation: under the fixed concentration of enzyme and substrate, the inhibition constant (K of measuring competitive inhibitor Ac-D-(D-Gla)-L-1-(Cha)-C-OH (27), Ac-DTEDVVA (Nva)-OH and Ac-DTEDVVP (Nva)-OH _i), according to the dynamic (dynamical) Michaelis-Menten equation of the competitive inhibition that rearranges: v _o/ v _i=1+[I] _o/ (K _i(1+[S] _o/ K _m)), v wherein _oBe the original speed that does not suppress, v _iBe in any inhibitor concentration ([I] that provides _o) the original speed of inhibitor under existing, [S] _oThe concentration of substrate that is to use is drawn v _o/ v _iTo inhibitor concentration ([I] _o) curve.With the data that linear regression fit obtains, use the slope that obtains, 1/ (K _i(1+[S] _o/ K _m) calculating K _iValue.The Ki of some The compounds of this invention gained ^*Value (in nmole) sees the following form shown in 3:

Table 3

Though in conjunction with specific embodiments set forth above the present invention has been described, wherein many substitute, improve and other to change those of ordinary skills be conspicuous.All substitute, improve and change and all fall in aim of the present invention and the scope.

Claims

1. compound, or the enantiomorph of described compound, steric isomer, rotational isomer, tautomer, diastereomer and racemic modification, or described compound pharmacy acceptable salt, solvate or ester, described compound has universal architecture shown in the formula I:

Formula I

Wherein:

E is C (H) or C (R);

L is C (H), C (R), CH ₂C (R) or C (R) CH ₂

Y is selected from the lower section:

Y wherein ³⁰Be selected from:

Wherein u is numerical value 0-1;

X is selected from O, NR ¹⁵, NC (O) R ¹⁶, S, S (O) and SO ₂

G is NH or O; With

2. the compound of claim 1, wherein R ¹Be NR ⁹R ¹⁰, and R ⁹Be H, R ¹⁰Be H or R ¹⁴, R wherein ¹⁴Be H, alkyl, aryl, assorted alkyl, heteroaryl, cycloalkyl, alkyl-aryl, alkyl-heteroaryl, aryl-alkyl, thiazolinyl, alkynyl or heteroaryl-alkyl.

3. the compound of claim 2, wherein R ¹⁴Be selected from:

4. the compound of claim 1, wherein R ²Be selected from the lower section:

5. the compound of claim 1, wherein R ³Be selected from:

R wherein ³¹Be OH or O-alkyl; With

R ³²Be H, C (O) CH ₃, C (O) OtBu or C (O) N (H) tBu.

6. the compound of claim 5, wherein R ³Be selected from the lower section:

7. the compound of claim 1, wherein G is NH.

8. the compound of claim 7, wherein Y is selected from the lower section:

Y wherein ³²Be selected from:

Y ³⁰Be selected from:

Wherein u is numerical value 0-1;

And R ¹⁹Be selected from H, alkyl, phenyl or benzyl.

9. the compound of claim 8, wherein T ₁And T ₂Can be identical or different, independently be selected from separately:

Or part:

Representative combines:

And T ₃Be selected from:

10. the compound of claim 1, wherein part:

Be selected from following structure:

11. the compound of claim 10, wherein part:

Be selected from following structure:

12. the compound of claim 11, wherein part:

Be selected from following structure:

13. the compound of claim 1, wherein R ¹Be NHR ¹⁴, R wherein ¹⁴Be selected from:

R ²Be selected from the lower section:

R ³Be selected from the lower section:

Y ³⁰Be selected from:

Y wherein ³⁰Also be selected from:

Y wherein ³⁰Also be selected from:

Y ³²Be selected from:

And Y ¹²Be selected from H, CO ₂H, CO ₂Me, OMe, F, Cl, Br, NH ₂, N (H) S (O ₂) CH ₃, N (H) C (O) CH ₃, NO ₂, NMe ₂, S (O ₂) NH ₂, CF ₃, Me, OH, OCF ₃And C (O) NH ₂

And Y ³³Be selected from:

And T ₃Be selected from:

And part:

For:

14. a medicinal compositions, described composition comprise the compound of at least a claim 1 as activeconstituents.

15. the medicinal compositions of claim 14, described composition are used for the treatment of the diseases associated with HCV.

16. the medicinal compositions of claim 15, described composition also comprise at least a pharmaceutically acceptable carrier.

17. the medicinal compositions of claim 16, described composition also contains at least a antiviral.

18. the medicinal compositions of claim 17, described composition also contain at least a Interferon, rabbit in addition.

19. the medicinal compositions of claim 18, wherein said at least a antiviral is a ribavirin, and described at least a Interferon, rabbit is alpha-interferon or Peg-Intron.

20. the method for treatment and HCV diseases associated, described method comprises needs the patient of this treatment medicinal compositions, and said composition comprises the compound of at least a claim 1 for the treatment of significant quantity.

The method of 21 claims 20 wherein saidly gives to be oral or subcutaneous administration.

22. the purposes of the compound of claim 1 in the preparation medicine, wherein said medicine is used for the treatment of the diseases associated with HCV.

23. one kind prepares the method that is used for the treatment of with the medicinal compositions of HCV diseases related, described method comprises that the compound that makes at least a claim 1 fully contacts with at least a pharmaceutically acceptable carrier is rational.

24. compound with HCV protease inhibiting activity, or the enantiomorph of described compound, steric isomer, rotational isomer, tautomer, diastereomer and racemic modification, or the pharmacy acceptable salt of described compound, solvate or ester, described compound is selected from down the compound of array structure:

25. the medicinal compositions of treatment and HCV diseases related, described composition comprises the compound and the pharmaceutically acceptable carrier of one or more claims 24 for the treatment of significant quantity.

26. the medicinal compositions of claim 25, described composition also contains at least a antiviral.

27. the medicinal compositions of claim 26, described composition also contain at least a Interferon, rabbit or PEG-alpha-interferon conjugates.

28. the medicinal compositions of claim 27, wherein said at least a antiviral is a ribavirin, and described at least a Interferon, rabbit is alpha-interferon or Peg-Intron.

29. the method for treatment and hepatitis C virus (" HCV ") diseases associated, described method comprises the compound of one or more claims 24 that give significant quantity.

30. regulate the active method of hcv protease for one kind, described method comprises makes HCV proteolytic enzyme contact with the compound of one or more claims 24.

31. a treatment, prevent or alleviate the method for one or more hepatitis C symptoms, described method comprises the compound of one or more claims 24 for the treatment of significant quantity.

32. the method for claim 31, wherein said HCV proteolytic enzyme is NS3/NS4a proteolytic enzyme.

33. the method for claim 32, wherein said one or more compounds suppress HCVNS3/NS4a proteolytic enzyme.

34. regulate hepatitis C virus (HCV) polypeptide method for processing for one kind, described method comprises makes the composition that contains the HCV polypeptide under the condition of the described polypeptide of processing, contacts with the compound of one or more claims 24.

35. the method for treatment and HCV diseases associated, described method comprises needs the patient of this treatment medicinal compositions, described composition comprises at least a compound for the treatment of significant quantity or enantiomorph, steric isomer, rotational isomer, tautomer, diastereomer and the racemic modification of described compound, or the pharmacy acceptable salt of described compound, solvate or ester, described compound is selected from following compound:

36. the compound of claim 1, described compound are purified form.